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Abstract

PHARMACOLOGICAL IMPLICATIONS OF ADENOSINE 2A RECEPTORDOPAMINE TYPE 2 RECEPTOR HETEROMERIZATION
By Candice Nicole Hatcher-Solis, B.A.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2016
Director: Diomedes E. Logothetis, Ph.D.
Professor and Chair, Department of Physiology and Biophysics

G protein-coupled receptors (GPCRs) are heptahelical, transmembrane proteins that
mediate a plethora of physiological functions by binding ligands and releasing G
proteins that interact with downstream effectors. GPCRs signal as monomers,
complexes of the same receptor subtype (homomers), or complexes of different
receptor subtypes (heteromers). Recently, heteromeric GPCR complexes have become
attractive targets for drug development since they exhibit distinct signaling and cellspecific localization from their homomeric counterparts. Yet, the effect of
heteromerization on the pharmacology of many GPCR homomers remains unknown.
Therefore, we have undertaken the task to examine the effect of heteromerization on Gs
signaling through the adenosine 2A receptor (A2AR) and Gi signaling through the
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dopamine type 2 receptor (D2R) since the A2AR-D2R heteromer is an emerging
therapeutic target for Parkinson’s disease (PD). We examined the effect of
heteromerization on A2AR and D2R homomeric signaling using electrophysiology and
the Xenopus laevis oocyte heterologous expression system. G protein-coupled inwardly
rectifying potassium channels (GIRKs) were used as reporters for Gi signaling because
activation leads to direct Gbeta-gamma (Gβγ)-mediated stimulation of the GIRK current.
We also coupled GIRK channels to Gs signaling by overexpressing Gαs and signaling
through Gαsβγ. Our electrophysiological assay is innovative because it allows us to
optimize the conditions of heteromerization and directly observe GPCR signaling at the
G protein level. Our data demonstrate that heteromer formation alone decreases
dopamine-elicited Gi signaling through the D2R and CGS-21680-elicited Gs signaling
through the A2AR. Furthermore, this reciprocal antagonism was predominately due to
changes in efficacy versus potency. We also examined crosstalk observing that
applying agonists or antagonists to the adjacent receptor further modulate this inhibition
with the combination of agonists and antagonists relieving inhibition. Mutating the A2ARD2R heteromer interface abrogated all of the aforementioned ligand-induced effects on
G protein signaling through the A2AR-D2R heteromer. We are currently aiming to
validate our results from the oocyte experiments with an in vivo model. Our data further
elucidate the effect of various ligands on G protein signaling through the A2AR- D2R
heteromer, which may facilitate future studies that examine A2AR-D2R heteromer
signaling.

xiv

Chapter 1 INTRODUCTION

1.1 GPCR signaling
GPCRs are critical for mediating many physiological and pathophysiological
processes and are thus located on almost every cell type. There are over 800 genes
encoding GPCRs in the human genome with distinct tissue and subcellular profiles (Lin
2013). GPCRs have an overall conserved structure including an extracellular amino
terminus, seven transmembrane (TM) alpha helices, an intracellular carboxy terminus,
and loops (3 extracellular and 3 intracellular) connecting the 7 TM helices (Ji,
Grossmann et al. 1998). Various stimuli activate GPCRs including hormones,
neurotransmitters, odorants, tastants, small molecules, ions, and photons. The majority
of GPCR signaling involves transducing extracellular stimulation into intracellular
signaling events through G proteins. GPCR-mediated G protein signaling involves the G
protein heterotrimer that consists of Gα, Gβ, and Gγ subunits (Lefkowitz 2007). Each
subunit has distinctive isoforms including 16 Gα, 5 Gβ, and 14 Gγ isoforms that
assemble in distinct combinations with GPCRs (Milligan and Kostenis 2006). Overall, G
protein signaling can be functionally grouped into 4 families: Gαi, Gαs, Gαq, and Gα12/13.
These G proteins have canonical signaling pathways regulating effector proteins, such
as enzymes, ion channels, and other proteins that in turn modify various intracellular
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second messengers that ultimately mediate physiological responses (Neves, Ram et al.
2002).
The molecular rearrangements of the Gα and Gβγ subunits of the heterotrimer
mediate G protein signaling through GPCRs. In the absence of ligand, the GPCR is in
an inactive state and the Gα subunit of the heterotrimer, which contains the guanine
nucleotide binding site is bound to guanine diphosphate (GDP) forming an inactive
GαGDPβγ heterotrimer complex (Bunemann, Frank et al. 2003). Ligand binding to the
GPCR promotes a conformational change in the receptor that is transmitted to the Gα
subunit increasing its affinity for guanine triphosphate (GTP) and promoting the
exchange of GDP for GTP (Birnbaumer, Abramowitz et al. 1990). The ligand-bound,
activated receptor is thus serving as a guanine exchange factor (GEF). The exchange
of GDP for GTP is the rate-limiting step in activating the G protein. Next, there is a
conformational change allowing the activated GαGTP subunit and the Gβγ subunits to
interact with downstream effectors such as adenylyl cyclases (AC), phospholipases, ion
channels, and phosphodiesterases (Fig. 1.2), (Hatcher-Solis et al. 2014). Hydrolysis of
GTP to GDP by the intrinsic GTPase activity of the Gα subunit promotes a
conformational rearrangement of the Gα and Gβγ subunits into the inactive GαGDPβγ
heterotrimer complex (Fig. 1.1) (Li, Wright et al. 2007). GTPase activating proteins
(GAPs) including regulator of G protein signaling (RGS) proteins accelerate the
hydrolysis of GTP to GDP inactivating G proteins (Li, Wright et al. 2007). G protein
signaling is also modulated by cholera toxin (CTX) and pertussis toxin (PTX). CTX ADPribosylates the Gα subunit of Gs proteins at Arg-201 disrupting intrinsic GTPase activity
rendering the Gαs protein constitutively active (Aktories 2011). Whereas, PTX ADP-
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ribosylates the Gα subunit of Gi proteins in the c-terminal Cys-351 moiety functionally
uncoupling Gi proteins from receptors and reducing their activation (Locht, Coutte et al.
2011).
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1.2 The A2AR
Adenosine (ADO) is an endogenous nucleoside produced by the metabolism of
adenosine triphosphate (ATP) and released along with glutamate from nerve terminals
and astrocytes (Fuxe, Marcellino et al. 2010). ADO acts on A1, A2A, A2B and A3
receptors (Ferre, Quiroz et al. 2008). These receptors are further categorized based on
their ability to stimulate or inhibit the activity of AC. Both the A2A and A2B receptors
couple to Gs through residues in the 3rd intracellular loops of the receptors and stimulate
the activity of AC. However, the A1 and A3 receptors couple to Gi through residues in
the 3rd intracellular loop and carboxy terminus of the receptors and inhibit the activity of
AC (Cabello, Gandia et al. 2009). The A1 and the A2 receptors function as the two main
adenosine receptors in the central nervous system (CNS) (Ferre, Quiroz et al. 2008).
Unlike the widespread distribution of the A1R throughout the brain, the A2 receptor is
primarily localized in the striatum and mainly concentrated in the GABAergic
striatopallidal neurons (Fuxe, Marcellino et al. 2010). Ultrastructural studies suggest
that A2ARs are localized predominantly in the post-synaptic dendrites and dendritic
spines of striatal GABAergic neurons even though there is some localization on the presynaptic glutamatergic terminals. The predominantly post-synaptic localization of A2AR
indicates the significant role adenosine plays in modulating inhibitory output from striatal
neurons (Hettinger, Lee et al. 2001).
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The A2AR couples to Gs/olf with Golf being the more abundant Gs family G protein
in the striatum. Via coupling to GS/olf proteins, A2AR stimulates adenylyl cyclase and
activates the cAMP- protein kinase A (PKA) signaling pathway. This signaling cascade
results in the phosphorylation of dopamine and cAMP-regulated phosphoprotein 32 kDa
(DARPP-32), cAMP response element binding protein (CREB), and AMPA receptors.
Accumulation of cAMP leads to the increase in PKA activation which phosphorylates
DARPP-32 and CREB resulting in the activation of mitogen-activated protein kinases
(MAPK), which in turn leads to an increase in expression of different genes such as cfos and preproenkephalin in GABAergic, enkephalinergic striatal neurons (Ferre et al.
2008, Fig.1.3).
In 2004, Canals et al. provided the first evidence of A2AR homodimerization.
Förster resonance energy transfer (FRET), bioluminescence resonance energy transfer
(BRET), and immunoblotting were employed to demonstrate that in transfected HEK293 cells the A2AR exists in monomeric and homomeric forms. Using cell surface
biotinylation experiments, the authors determined that 90% of A2ARs exist as
homodimers (Canals, Burgueno et al. 2004). Subsequent studies by Gandia and
colleagues in 2008 using bimolecular fluorescence complementation (BiFC) provided
additional evidence that A2ARs can form higher order oligomers. The ability of A2ARs to
form homomers has significant implications for the subunit stoichiometry of heteromers
that the A2AR forms with various receptors (Gandia, Lluis et al. 2008).
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1.3 The D2R
Dopamine (DA) is essential for modulating a plethora of central nervous system
(CNS) functions including mood, feeding, reward, fear, cognition, attention, arousal, and
voluntary movement (Fuxe, Marcellino et al. 2010). Most dopaminergic innervation in
the mammalian brain is through 4 major pathways named the nigrostriatal, mesolimbic,
mesocortical, and tuberoinfundibular systems. The majority of dopaminergic neurons in
brain modulate fast neurotransmission mediated by GABA and glutamate. DA is the
endogenous ligand for five different receptors (D1R, D2R, D3R, D4R, D5R) (Cabello,
Gandia et al. 2009) and is synthesized locally in neurons from its immediate precursor
L-DOPA, which is synthesized directly from the amino acid tyrosine. DA receptors can
be further subdivided as being Gs coupled activators of AC and D1-like (D1, D5), or Gi
coupled inhibitors of AC and D2-like (D2R, D3R, D4R) (Hasbi, O'Dowd et al. 2011). The
D1R and D2R are found most prominently in GABAergic striatopallidal neurons and are
pivotal to motor control through the direct and indirect pathway. The D1-like receptors
are predominantly localized postsynaptically, whereas the D2-like receptors function
presynaptically as autoreceptors on dopaminergic neurons and postsynaptically on
dopamine targeting neurons (Boyd and Mailman 2012).
The D2R has two splice variants the D2SR (short isoform), which functions
presynaptically as an autoreceptor and the D2LR (long isoform), which functions
postsynaptically with important implications for motor control. These two splice variants
differ by 29 amino acids in the 3rd intracellular loop (Beaulieu and Gainetdinov 2011).
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Presynaptically localized autoreceptors provide a negative feedback regulating neuronal
firing, synthesis, and release of dopamine in response to changing extracellular
dopamine levels. Presynaptic D2Rs function to reduce dopamine release in the synapse
that ultimate leads to decreased motor activity (Boyd and Mailman 2012). However,
stimulation of postsynaptic D2Rs results in increased locomotor activity. Pre- and
postsynaptic D2Rs exert the aforementioned functional effects through Gi/o protein
signaling (Beaulieu and Gainetdinov 2011).
G protein signaling through D2Rs regulates ion channels with important
implications for neuronal excitability. DA binding to D2Rs induces a conformational
change activating the D2R resulting in the liberation of the Gβγ subunits from the G
protein heterotrimer. Next, the liberated Gβγ subunits bind to voltage dependent calcium
channels (VDCC) reducing calcium (Ca2+) influx (Ikeda 1996),(Herlitze, Garcia et al.
1996). Without Ca2+ influx depolarizing the membrane, the medium spiny neuron (MSN)
remains hyperpolarized near the potassium equilibrium potential. The released Gβγ
subunits also bind to the amino and carboxy terminals of GIRKs potentiating their
activity (Logothetis, Kurachi et al. 1987). Increased potassium efflux also hyperpolarizes
neurons reducing excitability (Fig.1.4). The ability of the D2R to inhibit neuronal
excitability is opposed by adenosine (ADO) activating the A2AR (Ferre, Ciruela et al.
2004).
In 2009, Han and colleagues engineered an obligate D2R homodimer to elucidate
G protein signaling through the D2R homomer. Using a Gq signaling based calcium
mobilization assay, an obligate D2R homodimer was engineered by expressing a wildtype (WT) D2R protomer incapable of signaling through endogenous Gq proteins in HEK
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cells and a second truncated D2R protomer fused to a chimeric Giq protein unable to
signal independently due to steric hindrance, but whose signaling was rescued by the
WT D2R protomer. These obligate D2R homodimers functioned similarly to the GABABR
requiring both protomers to efficiently bind ligands and signal through G proteins. This
study demonstrated that agonist binding to one D2R protomer produced activation, but
agonist binding to both D2R protomers inhibited activation. Additionally, agonist binding
to one D2R protomer and an inverse agonist binding to the second D2R protomer
enhanced signaling. These studies suggest that signaling through D2R homomers is
asymmetrical with activation requiring differential conformational changes from each
protomer (Han, Moreira et al. 2009).
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1.4 Evidence for A2AR-D2R heteromerization
Biochemical and biophysical techniques have provided evidence that the A2AR
and D2R form a functional heteromeric complex. In 2002, Hillion et al. demonstrated colocalization of the A2AR and D2R in SH-SY5Y human neuroblastoma cells stably
transfected with D2R using double immunofluorescence experiments (Fig. 1.5A).
Immunolabeling experiments were also conducted in neuronal primary cultures of rat
striatum whereby most neurons exhibited A2AR-D2R immunoreactivity in the dendrites.
In the same study, co-immunoprecipitation experiments were conducted in membrane
preparations from D2R transfected SH-SY57 neuroblastoma cells and mouse fibroblast
Ltk- stably transfected with D2R and transiently co-transfected with the A2AR. Western
blots were also utilized to demonstrate co-localization since probing with an antibody
targeting the D2R was able to pull down the A2AR-D2R heteromer out of solution (Hillion,
Canals et al. 2002).
Furthermore, in 2003 Canals et al. used FRET in HEK-293T cells transfected
with D2R-GFP2 and A2AR-YFP to determine if the receptors were close enough in
proximity to produce energy transfer. The FRET efficiency was determined to be in the
range of 23-25%, while there was significantly lower FRET efficiency in the negative
control using D2R-GFP2 and CD4-YFP demonstrating the specificity in energy transfer
between D2R-GFP2 and A2AR-YFP. Additionally, BRET saturation curves in HEK-293T
cells co-transfected with a constant amount of A2AR-Rluc construct with increasing
concentrations of the D2R-YFP plasmid displayed a positive BRET signal for the
9

transfer of energy. The BRET signal increased as a hyperbolic function of YFP fusion
construct (Fig.1.5B). BRET experiments were repeated in the presence of cyclodextrin
to disrupt membrane rafts to preclude the notion that energy transfer was occurring in
closely located receptors within plasma membrane microdomains (Canals, Burgueno et
al. 2004). A negative control BRET experiment with A2AR-Rluc and GABABR2-YFP lead
to an undetectable BRET signal. Moreover, undetectable energy transfer was observed
in BRET saturation experiments using the A2AR and a chimeric dopamine receptor type
1 (D1R) –D2R, where the regions of the D2R known to interact with the A2AR (helices 5
and 6, intracellular loop 3) were replaced with the corresponding regions of the D1R,
which does not interact with A2AR (Canals, Marcellino et al. 2003, Ferre, Ciruela et al.
2004).
In 2011, Trifilieff and colleagues used the proximity ligation assay (PLA) to
detect co-localization of endogenous A2ARs and D2Rs in ex vivo preparations from
mouse striatum. These studies were motivated by concerns that A2AR-D2R colocalization may not be physiologically relevant because previous studies demonstrating
co-localization were performed by overexpressing the A2AR and D2R in heterologous
expression systems. The advantage of PLA is that it can determine the close proximity
of endogenous proteins in their native state at the single molecule level with high
specificity. PLA performed on murine striatal slices produced a positive signal for colocalization of the A2AR and D2R that was absent when the same probes were used in
knock out (KO) A2AR and D2R mice. These experiments were critical for demonstrating
the anatomical relevance of A2AR-D2R co-localization in native tissue (Trifilieff, Rives et
al. 2011).
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1.5 The A2AR-D2R heteromer Interface
Additional experiments have been conducted to determine the A2AR-D2R
heteromer interface. Canals et al. (2003) performed rigid body docking simulations on
minimized structures of the A2AR and D2R to determine potential A2AR-D2R heteromer
interfaces. The two populations of structures obtained had the amino terminal portion of
the 3rd intracellular loop of the D2R approaching the 4th helix and carboxy terminal
portion of the A2AR. These structures had high docking scores and were consistent with
BRET experiments involving the D1R-D2R chimera showing that the 3rd intracellular loop
of the D2R is part of the heteromer interface (Canals, Marcellino et al. 2003).
Motivated by the work of Canals et al., Circuela at al. (2004) used biochemical
pull down assays and mass spectrometry to demonstrate that heteromerization
depends on electrostatic interactions between an arginine-rich epitope of the amino
terminal segment of the 3rd intracellular loop of the D2R and phosphorylated Ser374 in
the carboxy terminus of A2AR (Fig.1.6). Pull down assays were performed where a GST
fusion protein containing the carboxy terminal domain of A2AR was able to pull down the
whole D2R solubilized from transfected HEK cells. Furthermore, a peptide of the
arginine rich 3rd intracellular loop of the D2R was able to pull down the carboxy terminus
of the A2AR as well as the whole A2AR solubilized from transfected HEK-293 cells. Mass
spectrometry also showed that the arginine rich 3rd intracellular loop of D2R binds the
carboxy terminus of the A2AR containing the phosphorylated serine residue (Ciruela,
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Burgueno et al. 2004). Likewise, Borroto-Escuela et al. (2010) demonstrated that
mutagenesis of Ser374 to alanine decreased A2AR-D2R interaction (Figs. 1.6 and 1.7).
BRET saturation curves in transfected cells established that A2AR-mediated inhibition of
D2R agonist binding and Gi signaling was also abolished by the A2AR(Ser374) to alanine
mutation. Thus, an electrostatic interaction between the arginine rich 3rd intracellular
loop of the D2R and the phosphorylated Ser374 of the carboxy terminal A2AR could
mediate A2AR-D2R heteromerization (Borroto-Escuela, Marcellino et al. 2010).
In 2015, Bonaventura and colleagues used FRET and PLA to demonstrate that
TM 5s of the A2AR and D2R are involved in heteromerization. FRET experiments were
conducted in HEK-293 cells transfected with the A2AR fused to the YFP Venus amino
terminal hemiprotein and the D2R fused to the YFP Venus carboxy terminal
hemiprotein. A significant fluorescent signal was obtained indicating fusion of the aminio
and carboxy terminal YFP hemiproteins and A2AR-D2R heteromerization. Next, the
experimenters used HIV TAT-fused interfering peptides for TM 5 and 7 of each receptor
to determine the heteromer interface. Peptides for TM 5, but not TM 7 of the A2AR and
D2R were able to disrupt fluorescence complementation. Using sheep striatal brain
slices in a PLA, endogenous A2AR-D2R heteromerization was shown in the same study.
Similar to the FRET experiments, interfering HIV TAT peptides from TMs 5 and 7 were
used in the PLA and TM 5 but not TM 7 abolished the PLA signal. These findings
demonstrate that TM 5 of the A2AR and D2R form the heteromer interface as these
peptides disrupted fluorescence complementation and the PLA signal (Bonaventura,
Navarro et al. 2015).
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1.6 Reciprocal antagonistic A2AR-D2R interactions
The antagonistic interaction involving the ability of the A2AR to modulate the
effect of D2Rs on ligand binding, neurotransmitter release, neuronal excitability, and
motor activity is critical for striatal function (Ferre, Quiroz et al. 2008). Several different
research groups have demonstrated an antagonistic A2A-D2R interaction using
competitive radioligand-binding experiments in membrane preparations from transfected
cell lines, and in human and rat striatum. In these experiments, the application of a
selective A2AR agonist diminished the capacity of a D2R agonist to displace the binding
of a discriminatory D2R ligand (Ferre, von Euler et al. 1991, Dasgupta, Ferre et al. 1996,
Kull, Ferre et al. 1999, Salim, Ferre et al. 2000, Diaz-Cabiale, Hurd et al. 2001).
Subsequent experiments established the antagonistic A2AR-D2R interaction
whereby stimulating the A2AR counteracts D2R mediated inhibition of neurotransmitter
release (Ferre, Quiroz et al. 2008). Ferré et al. (1993) showed the antagonistic A2ARD2R interaction experimentally through in vivo microdialysis experiments whereby
perfusion of a D2R agonist into the dorsal striatum caused a decrease in the
extracellular levels of the neurotransmitter GABA in the globus pallidus (Ferre, Snaprud
et al. 1993). Conversely, when an A2AR agonist was perfused, there were no direct
effects, but the action of a D2R agonist was blocked (Ferre, Snaprud et al. 1993). In the
ventral striatum, D2Rs exert a more tonic stimulation through endogenous DA on
neurotransmitter release from GABAergic enkephalinergic neurons. Consequently,
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ventral striatal perfusion of an A2AR agonist increased the extracellular levels of GABA
in the ventral pallidum acting as a D2R antagonist (Ferre, O'Connor et al. 1994).
The ability of the A2AR to antagonize D2R mediated inhibition of neuronal firing
has also been well characterized (Ferre, Quiroz et al. 2008). Striatal output is
determined by the firing frequency of inhibitory GABAergic MSNs. Corticospinal inputs
to the striatum depolarize GABAergic MSNs from a resting hyperpolarized membrane
potential activating D2Rs preventing MSNs from transitioning to a more depolarized
membrane potential. Azdad et al. (2009) conducted experiments utilizing perforated
patch clamp recordings from brain slices to demonstrate the role of A2AR-D2R
interactions in regulating the membrane potential transitions of striatopallidal neurons.
Application of a D2R agonist hyperpolarized the striatal MSNs and abolished the firing
(Azdad, Gall et al. 2009). Ensuing application of an A2AR agonist failed to modify
neuronal state transitions or firing frequency, but reversed the effect of the D2R
activation. The ability of A2AR agonists to disinhibit neuronal firing was blocked by A2AR
antagonists. Furthermore, A2AR ligands had no effect on neuronal firing in A2AR KO
mice (Azdad, Gall et al. 2009).
Similar to neurotransmitter release and neuronal excitability, motor activity is also
governed by the antagonistic A2A-D2R interaction. Several experiments have revealed
the ability of selective A2AR ligands to offset or potentiate the motor activation created
by D2R agonists (Ferre, Herrera-Marschitz et al. 1991, Rimondini, Ferre et al. 1998,
Ferre, Popoli et al. 2001). Ferré et al. (2009) performed behavioral experiments in
neurotoxin induced DA depleted rats showing that the A2AR agonist CGS 21680
attenuated the effects of a D2R agonist quinpirole on turning behavior (Ferre, Baler et al.
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2009). Accordingly, Stromberg et al. 2000 demonstrated that an A2AR antagonist MSX-3
significantly potentiated the quinpirole induced turning behavior of DA denervated rats.
These experiments argued for a specific A2AR-D2R interaction in enkephalinergic striatal
neurons because MSX-3 did not significantly alter the turning behavior of rats given the
D1R agonist SKF 38393 (Stromberg, Popoli et al. 2000).
Fewer studies have examined antagonism of the D2R on A2AR signaling and
binding. Signaling through the A2AR results in cAMP accumulation, CREB
phosphorylation and an increase in c-fos expression. Under physiological conditions,
the D2Rs exhibit a steady activation that impedes the ability of A2ARs to signal through
the cAMP-PKA pathway (Konradi and Heckers 1995). Experimental demonstrations in
rodent striatum show that in vivo administration of D2R antagonists produces a
significant increase in the PKA dependent phosphorylation of DARPP-32 or the AMPA
receptor resulting in an increase in the expression of c-fos or preproenkephalin genes.
This increase in gene expression depends on the ability of the antagonist to block the
D2R and release A2AR signaling stimulated by endogenous ADO (Pollack and Fink
1995). In the antagonistic A2AR-D2R interaction at the second messenger level, the D2R
receptor lacks an independent effect on gene expression, but stimulation of the D2R
receptor counteracts the effects of A2AR receptor stimulation (Svenningsson, Lindskog
et al. 2000).
In 2013, Fernandez-Duenas and colleagues developed a novel A2AR fluorescent
ligand MRS5424 and used real-time FRET along with flow cytometry to examine the
effect of the D2R on A2AR agonist binding. HEK-293 cells were transfected with A2ARCFP and D2R-AGT and co-localization of the A2AR and D2R was visualized using SNAP

15

tag technology. Real-time FRET experiments demonstrated that binding of the A2AR
agonist MRS5424 was reduced upon perfusion of the D2R agonists pramipexole,
rotigotine, and apomorphine. In cells transfected only with the A2AR, perfusion of the
previously mentioned D2R agonists had no effect on MRS5424 binding. Flow cytometry
was also conducted with similar results to the real-time FRET experiments where the
D2R agonists pramipexole, rotigotine, and apomorphine caused a significant reduction
in MRS5424 binding to the A2AR. These experiments provide evidence for agonists
binding to the D2R acting as negative allosteric modulators of agonist binding to the
A2AR (Fernandez-Duenas, Gomez-Soler et al. 2013).
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1.7 The Basal Ganglia and the A2AR-D2R Heteromer
Essential for the planning and initiation of movement, the basal ganglia are a
group of subcortical nuclei consisting of the caudate nucleus, putamen, globus pallidus,
substantia nigra, and the subthalamic nucleus (STN). The purpose of the basal ganglia
circuit is to process incoming signals from the cortex and to relay an output signal to the
cortex through the thalamus to execute voluntary movement. Consisting of the caudate
nucleus, putamen, and nucleus accumbens, the striatum is the main input structure of
the basal ganglia circuit (Blandini, Nappi et al. 2000). The major neural innervations of
the striatum that are relevant to our study consist of excitatory glutamatergic projections
from nearly all cortical areas and dopaminergic inputs from the substantia nigra pars
compacta (Fig. 1.9(McGeorge and Faull 1989, Blandini, Nappi et al. 2000)). MSNs
comprise over 95% of the striatum with GABA being the main neurotransmitter of these
neurons (Kemp and Powell 1971, Kita and Kitai 1988). Within the MSNs, GABA can be
co-localized with either enkephalin or substance P/dynorphin. Enkephalinergic MSNs
contain A2ARs and D2R and project to the external segment of the globus pallidus;
whereas, dynorphinergic MSNs contain A1Rs and D1Rs and project to the internal
segment of the globus pallidus (Fig. 1.9). The striatal organization of enkephalinergic
and dynorphinergic MSNs form the basis for the direct and indirect motor pathways
(Blandini, Nappi et al. 2000).
Two main striatal motor pathways regulate the output from the basal ganglia: the
direct and indirect pathways. We will focus on the indirect pathway since it involves the
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A2AR-D2R heteromer and is implicated in PD (Kull, Ferre et al. 1999). Under
physiological conditions, striatal MSNs expressing the A2AR-D2R heteromer receive
dopaminergic input from the substantia nigra pars compacta. In the striatum, D2R
signaling inhibits neuronal excitability and reduces inhibitory GABAergic output to the
external segment of the globus pallidus (Gpe) (Lang and Lozano 1998, Blandini, Nappi
et al. 2000). Through heteromerization, the A2AR is critical in modulating neuronal
excitability and GABA release by counterbalancing D2R signaling. Next, the tonically
active inhibitory neurons of the Gpe relay to provide tonic, inhibitory GABAergic
projections to the STN. Then, the STN conducts transient, glutamatergic excitatory
output to the internal segment of the globus pallidus (Gpi). The Gpi subsequently sends
a tonic inhibition to the ventrolateral thalamus. Consequently, the ventrolateral thalamus
sends a transient excitatory projection to the motor cortex to initiate movement (Fig. 1.8
left, (Lang and Lozano 1998)). Overall, the signaling balance through the A2AR-D2R
heteromeric complex is a critical component of the indirect motor pathway regulating the
neuronal excitability of striatal GABAergic MSNs.
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1.8 The A2AR-D2R Heteromer and the significance for Parkinson’s disease
Discovered by James Parkinson in 1817, PD is the second most common
neurodegenerative disease affecting 1-2% of people over the age of 60. For most
patients, there is a slow progression of the disease between the ages of 50 and 70
followed by death 10 to 20 years later (Lang and Lozano 1998). The etiology of PD
remains unclear, but considerable research has led to the notion that genetic
predisposition and exposure to pesticides contributes to disease formation. The
hallmark of PD is the formation of Lewy bodies (aggregates of α-synuclein) and the
progressive deterioration of dopaminergic neurons in the substantia nigra pars
compacta (Lozano, Lang et al. 1998). After loss of approximately 80% of dopaminergic
neurons in the substantia nigra, Parkinsonian symptoms appear including a decrease in
spontaneous movement, postural instability, bradykinesia, rigidity, and a resting tremor
(Lang and Lozano 1998). These defects in motor function are attributable to increased
inhibitory output from the basal ganglia causing decreased thalamic activation of the
motor cortex (Lang and Lozano 1998).
In cases of PD, decreased homomeric dopaminergic signaling through the D2R
along with antagonism of the A2AR on the residual D2R signaling will increase inhibitory
GABAergic projections from the basal ganglia to the ventrolateral thalamus thus
diminishing excitatory thalamic output to the motor cortex (Fig.1.8 right, (Kull, Ferre et
al. 1999)). The excessive inhibition of thalamocortical projections causes Parkinsonian

19

symptoms. Currently, there is no cure for PD, but D2R agonists and A2AR antagonists
are used clinically to manage motor dysfunction (Jenner 2003).
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1.9 Antiparkinsonian therapeutics targeting the A2AR-D2R Heteromer
Symptomatic management of PD is based on using D2R agonists to mimic DA
mediated neurotransmission in the nigrostriatal pathway. Levodopa (L- DOPA), the
immediate precursor of DA, is highly effective in managing the early stages of PD
(Jenner 2003). However, adverse side effects caused by D2R agonists include nausea,
vomiting and hypotension. Chronic side effects include dyskinesia, psychosis and loss
of drug efficacy. Furthermore, D2R agonists do not alleviate the Parkinsonian symptom
of postural instability or address the neurodegeneration responsible for the advent of
motor dysfunction (Jenner 2003). In order to circumvent the problems associated with
D2R agonists, researchers have explored the use of A2AR antagonists based on the
well-characterized antagonistic interaction between the A2AR and the D2R.
A2AR antagonists that inhibit postsynaptic A2ARs in enkephalinergic MSNs would
be beneficial for the treatment of PD through inhibiting the indirect motor pathway and
increasing motor activity. However, A2AR antagonists that inhibit presynaptic A2ARs that
contact dynorphinergic MSNs would decrease glutamate release in the direct motor
pathway inhibiting motor activity. Thus, antiparkinsonian therapeutics targeting the A2AR
should have a higher affinity for postsynaptic versus presynaptic A2ARs. In 2011, Orrú
and colleagues used radioligand-binding experiments in stable cell lines containing
A2ARs, A2AR-D2R heteromers (postsynaptic A2ARs), and A2AR-A1R heteromers
(presynaptic A2ARs). Among the A2AR antagonists tested, SCH 442416 had the lowest
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affinity in cell lines containing A2AR-D2R heteromers whereas istradefylline (KW-6002)
had the highest relative affinity in cells containing A2AR-D2R heteromers. Additional
studies demonstrated that KW-6002 reduced motor impairment in neurotoxin induced
Parkinsonism animal models (Orru, Bakesova et al. 2011). Therefore, KW-6002 was
examined as a promising antiparkinsonian therapeutic as it targets postsynaptic A2ARD2R heteromers increasing motor activity.
The majority of information available on the effectiveness of A2AR antagonists in
PD patients was collected in clinical trials with KW-6002. Phase IIa clinical trials with
KW-6002 suggest that the drug has antiparkinsonian actions significantly reducing
motor deficits in advanced PD patients. According to the study, KW-6002 had no effect
on Parkinsonian symptoms when solely administered. However, when combined with a
low dose of L-DOPA, patients experienced improved motor function comparable to an
optimal dose of L-DOPA alone. Combining KW-6002 with L-DOPA reduced side effects
with patients experiencing milder dyskinesia, dizziness, insomnia and nausea. Only 5%
of patients experienced increased anxiety. When KW-6002 was co-administered with LDOPA, the half-life of L-DOPA was prolonged (Chen, Wang et al. 2013). Despite these
promising results, KW-6002 did not receive FDA approval in 2008, but it ignited further
studies into A2AR antagonists as antiparkinsonian drugs (Armentero et al. 2011). In
March of 2013, KW-6002 became the first A2AR antagonist approved for treatment of
PD in Japan. As of 2014, clinical trials were in progress for the following A2AR
antagonists: phase I for PBS-509, ST1535, ST4206 and V81444; phase II for
tozadenant. Learning more about signaling through the A2AR-D2R heteromeric complex
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will facilitate the development of novel and more efficacious medications for PD
(Armentero, Pinna et al. 2011).
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1.10 Conclusion
Homomeric G protein receptor signaling has been characterized for many years,
but recent data suggest that many GPCRs form oligomeric complexes with distinct
signaling properties. The effect of heteromerization on the pharmacology and signaling
of many GPCR homomers is still not well understood. Thus, GPCR heteromers provide
new therapeutic targets and research into the signaling of heteromers could provide
novel therapeutics for important diseases. The Gαs/olf coupled A2AR and the Gαi/o coupled
D2R are two distinct GPCRs that heteromerize in the dorsal and ventral striatopallidal
GABA pathway (Ferre, Quiroz et al. 2008). The physiological relevance of the A2AR-D2R
heteromer is based on receptor antagonism. A2ARs antagonize the inhibitory role of
D2Rs on neurotransmitter release, neuronal firing, and locomotor activity. There is
exaggerated antagonism of the D2R by the A2AR in Parkinson’s disease patients due to
decreased dopaminergic tone in the striatum (Kull, Ferre et al. 1999). Therefore, A2AR
antagonists are being explored as possible therapeutics for Parkinson’s disease
because they alleviate the A2AR inhibition of the D2R (Ferre, Ciruela et al. 2007). D2Rs
also antagonize A2AR agonist binding and at the second messenger level. The A2ARD2R heteromer is an emerging therapeutic target for dysfunctional dopaminergic
signaling and studies examining G protein signaling through the heteromer could yield
important insight for drug development.
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1.11 Hypothesis
Based on previous studies elucidating reciprocal antagonistic A2AR-D2R
interactions, we hypothesized that A2AR-D2R heteromerization would reduce both D2Rmediated Gi signaling and A2AR-mediated Gs signaling. To test our hypothesis, we
studied A2AR-D2R heteromer cross signaling by expressing the GPCRs as well as
reporter channels using the Xenopus oocyte heterologous expression system. Our
electrophysiological assay is innovative in that it will allow us to control the conditions of
heteromerization to tease apart the differences from homomeric or monomeric
signaling. By monitoring the current through the reporter channel, we found that A2ARD2R heteromerization inhibited both D2R-mediated Gi signaling and A2AR-mediated Gs
signaling even when the adjacent receptor was unliganded and perfusion of specific
ligand combinations targeting the A2AR-D2R heteromer induced crosstalk and
modulated this inhibition. After completing our in vitro experiments in Xenopus oocytes,
we transitioned to an in vivo system utilizing a novel optogenetics-microdialysis assay
and examined the effects of A2AR antagonists on striatal glutamatergic release. We
demonstrated that A2AR antagonists with a preferred presynaptic profile were able to
inhibit the release of glutamate; whereas, A2AR antagonists with a preferred
postsynaptic profile targeting the A2AR-D2R heteromer were not able to inhibit striatal
glutamate release.
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Figure 1.1 The G protein cycle. Ligand binding to the GPCR promotes a
conformational change in the receptor that is transmitted to the Gα subunit increasing its
affinity for guanine triphosphate (GTP) and promoting the exchange of GDP for GTP.
Next, the activated Gα subunit dissociates from the Gβγ subunits allowing interactions
with downstream effectors. Hydrolysis of GTP to GDP by the intrinsic or stimulated
GTPase activity of the Gα subunit promotes reassociation of the Gα and Gβγ subunits
into the inactive heterotrimer complex. Adopted from Li et al., 2007.
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Figure 1.2 Gi/o- and Gs-coupled Receptor Signaling. Receptor stimulation results in
the liberation of Gβγ subunits from the G protein heterotrimer that are free to bind to
nearby GIRKs potentiating their current. Adapted from Hatcher-Solis et al. 2014.
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Figure 1.3 A2AR Signaling. Diagram showing the predominantly postsynaptic
localization of A2ARs along with A2AR signaling.
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Figure 1.4 D2R Localization and Signaling. Diagram showing the pre- and
postsynaptic localization of D2Rs along with D2R signaling affecting neuronal excitability.
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Figure 1.5 A2AR and D2R Co-localization. (A) SH-SY5Y human neuroblastoma cells
stably transfected with D2R (a) A2AR immunoreactivity, (b) D2R immunoreactivity, and
(c) A2AR-D2R colocalization. Adapted from Hillion et al. 2002. (B) Competition BRET
saturation curve of HEK-293 cell co-transfected with A2AR and D2R. A2AR-Rluc and D2RYFP (squares) or A2AR-Rluc and GABABR2-YFP (triangle). Adapted from Canals et al.
2003.
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Figure 1.6 The A2AR-D2R Heteromer Interface. (A) WT D2R (red) with arginine rich 3rd
intracellular loop. D2R (blue) with arginine to alanine mutations in the 3rd intracellular
loop. (B) BRET saturation curve for A2AR-D2R (red) and A2AR-D2R(R-A) (blue). Adapted
from Circuela et al. 2004.
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Figure 1.7 The A2AR-D2R Heteromer Interface Continued. (A) Snake plot of the WT
A2AR. (B) BRET saturation curve of the D2R-Rluc and A2AR-YFP (red), D2R-Rluc and
A2AR-YFP(S374A, grey), D2R-Rluc and A2AR(DD)-YFP (white), and D2R-Rluc and
A2AR(SDD)-YFP (black). Adapted from Escuela et al. 2010.
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Figure 1.8 The Indirect Motor Pathway. Diagram of the indirect motor pathway (left)
and the alterations in signaling that occur during PD (right).
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Figure 1.9 Pre- and Postsynaptic Localization of A2ARs and D2Rs. A2ARs are colocalized with D2Rs postsynaptically in the dendritic spines of enkephalinergic medium
spiny neurons in the striatum. A2ARs are also co-localized with A1Rs presynaptically in
glutamatergic afferents to enkephalinergic and dynorphynergic medium spiny neurons.
D2R are similarly located presynaptically in glutamatergic and dopaminergic afferents
projecting to enkephalinergic and dynorphynergic medium spiny neurons. Adapted from
Ferre 2008.
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Chapter 2 MATERIALS AND METHDOS

2.1 Molecular Biology
The following cDNAs used in the Xenopus oocyte heterologous expression
system were subcloned into the pXOOM oocyte expression vector: mD2R, 3HA-hA2AR,
m-PHOS, D2R(9A), A2AR(S374A), Kir 3.2, and βARK. Previous studies in the lab
provided the following cDNAs subcloned into the pGEMHE oocyte expression vector Kir
3.1, Gαs, and PTX. Linearized and purified (Pure Link PCR Purification kit, Thermo
Fisher Scientific) plasmids were transcribed using an mMESSAGE mMACHINE T7
Transcription kit (Thermo Fisher Scientific). Mutations were performed using a standard
Pfu-based mutagenesis protocol and were verified using sequencing (Genewiz).

2.2 Reagents
CGS 21680, KW-6002, SCH44216, N6-cyclopentyladenosine, and paliperidone
were purchased from Tocris. Dopamine, amisulpride, adenosine, and quinpirole were
purchased from Sigma. SCH44216 used in the microdialysis experiments was kindly
provided by the CHDI foundation. CGS 21680, KW-6002, and SCH44216 were
dissolved in DMSO at a dilution that was less than 1% DMSO. Dopamine, amisulpride,
paliperidone, adenosine, N6-cyclopentyladenosine, and quinpirole were dissolved in
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water. SCH44216 used in the microdialysis experiments was dissolved in a mixture of
tween-80 detergent and DMSO.

2.3 Oocyte preparation and injection
Xenopus laevis (African clawed frog) colonies (Xenopus Express) were
maintained at the Virginia Commonwealth University according to IACUC approved
protocols. The Xenopus laevis surgeries conducted in this study were approved by
protocol AD20112: Heterologous Expression Studies in Xenopus laevis Oocytes.
Briefly, Xenopus were anesthetized with a buffered Tricaine solution and ovarian tissue
was excised unilaterally. Excised oocytes were defolliculated using a collagenase
solution following standard protocols (Logothetis, Movahedi et al. 1992). Oocytes were
then washed and incubated at 180 C in an OR2 solution with 2 mM Ca2+ and Penicillin/
Streptomycin antibiotics. Oocytes at stage V or VI of maturation were selected for
microinjection of 0.5-2 ng of cRNA suspended in DEPC treated water. Injected oocytes
were incubated for 2-3 days at 18 0C to allow for optimal protein expression.

2.4 Two-electrode voltage-clamp
Borosilicate glass tubing was pulled using a Flaming-Brown micropipette puller.
The micropipettes were then back filled with a 3 M KCl solution that was1.4% agarose.
Acceptable resistances for the micropipettes were between .1 and 1 MΩ. Two-electrode
voltage-clamp whole-cell current recordings for the Gi and Gs assay were performed
using a GeneClamp 500 amplifier (Axon Laboratories). Oocytes were held at 0 mV (Ek)
and the current was monitored using a 800 ms ramp protocol with a command potential
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from -80 mV to +80 mV to assess the inward and outward currents. Basal current
through the GIRK channel was measured in a ND96K solution (HK, 96 mM KCl, 10 mM
HEPES-K, 1 mM MgCl2, and 1.8 mM CaCl2. 3 mM Barium Chloride (Ba2+) in HK was
used to block the GIRK current. Only the Barium-sensitive current was used for the
statistical analysis. Each data set consisted of 5-10 recordings, each from separate
oocytes. Experiments were repeated using oocytes from at least 2 different frogs.

2.5 Experimental Mice
WT C57BL/6 mice (Charles River Laboratories) were housed four per cage and
kept on a 12 h light/ dark cycle with food and water available ad libitum. All mice used in
this study were maintained in accordance with the guidelines of the National Institutes of
Health Animal Care and the mouse research conducted to perform this study was
approved by the NIDA IRP Animal Care and Use Committee protocol no. 12-BNRN-73.

2.6 Craniotomy surgical procedures
For all craniotomy surgical procedures, mice were anesthetized with a
combination of ketamine and xylazine (NIDA Pharmacy) and placed in a stereotaxic
apparatus. For optogenetic-microdialysis experiments, mice received unilateral
injections of adeno-associated virus (AAV) encoding channel rhodopsin 2 (ChR2) fused
to enhanced yellow fluorescent protein (EYFP) under control of the CaMKII neuronal
promoter (AAV-CaMKIIa-hChR2(H134R)-EYFP; University of North Carolina core
vector facility) in the motor cortex. The coordinates of virus injection were 1.9 mm
anterior, 1.6 mm lateral, and 1.8 mm ventral with respect to bregma. See Quiroz, Orru

37

et al. 2016 for detailed a protocol of virus injection. Approximately, 4 weeks after virus
injection a modified microdialysis probe with an embedded light-guiding optic fiber
(Quiroz, Orru et al. 2016) was implanted in the striatum. The coordinates for probe
implantation were 0.3 mm posterior, 2.7 mm lateral and 4.2 mm ventral with respect to
bregma. The optogenetic microdialysis probes were fixed to the skull with dental cement
and acrylic resin.

2.7 Optogenetic stimulation
Optical stimulation was delivered by coupling the light guiding port of the
implanted optogenetic-microdialysis probe to a 473 nm solid-state laser module driven
by an electrical stimulator (Gross S88 Stimulator). Light was administered over a 20 min
period in 160 ms trains of 2 ms pulses at 100 Hz with a light intensity of 5-8 mW at the
probe tip. The light intensity delivered through the probe was measured using an
integrating sphere silicon photodiode power sensor designed for optical power
measurements independent of beam shape and divergence (model S144C, Thor labs).

2.8 In vivo Microdialysis
Microdialysis sampling was performed with optogenetic stimulation to analyze the
extracellular concentration of glutamate in the striatum of freely moving mice 48 hrs.
after probe implantation. An artificial cerebrospinal fluid (aCSF) containing the following
in mM (144 NaCl, 4.8 KCl, 1.7 CaCl2 and 1.2 MgCl2) was perfused through the
optogenetic-microdialysis probe for the entire duration of the experiment. Perfusion was
at a constant rate of 0.5 µL/min and drugs were delivered through intraperitoneal (i.p.)
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injection. Sampling was obtained manually at 10 min intervals for 180 minutes. The first
60 min were to examine basal glutamate measurements and the final 120 were to
examine extracellular glutamate release in response to drug administration followed by
20 min of optogenetic stimulation. Extracellular glutamate was measured by HPLC
coupled to a glutamate oxidase enzyme reactor and electrochemical detector (Eicom).
After the microdialysis experiments, the mice were anesthetized with Equithesin (NIDA
pharmacy) and perfused transcardially with 0.1 M PBS pH 7.4 followed by 4%
formaldehyde in 0.1 M PBS. Brains were stored in the same fixative for 2 hrs and then
stored in 30% sucrose in 0.1 M PBS for 48 hrs at 40 C. Brains were then sliced in 40 µm
coronal sections using a Leica CM3050S cryostat at -200 C. The brain slices were
collected in PBS and stored in antifreeze-buffered solution (20% ethylene glycol, 10%
glycerol, and 10% sucrose in PBS) at -800 C until processing. Slices were imaged using
confocal fluorescence microscopy acquired with a Zeiss microscope (Examiner Z1)
fitted with a confocal laser module (LSM-710, Zeiss).

2.9 Erk 1/2 Immunohistochemistry
Fixed brain slices (see previous section) were stained according to the protocol
detailed in Quiroz-Molina et al. 2015. Briefly, the brain slices were rinsed in PBS and
incubated in blocking buffer before incubation with rabbit polyclonal anti-phosphoThr202/Tyr204 ERK1/2 antibody in blocking buffer. Sections were then washed and
incubated in biotinylated goat anti-rabbit antibody. The samples were subsequently
washed and incubated in ABC reagent and washed again before treatment with DAB,
ammonium nickel sulfate, and hydrogen peroxide until development. The samples were

39

then mounted onto treated glass slides, dehydrated, cleared in xylene, and coverslipped
with DPX. Images were acquired using confocal microscopy (see previous section).

2.10 Statistics
All data were expressed as mean ± standard error of the mean (SEM), unless
otherwise indicated. Error bars in each figure represent standard error of the mean
(SEM). In the oocyte experiments, statistical significance between 2 groups was
assessed using an unpaired t-test with an assumption of unequal variance (OriginLab).
When multiple groups were analyzed, a one-way ANOVA followed by Tukey’s posthoc
test was used (OriginLab). Gi and Gs activities were determined by normalizing the druginduced current to the basal GIRK current in HK and subtracting out the barium
insensitive current. For the microdialysis experiments, extracellular glutamate
measurements were normalized to the basal measurements before optogenetic
stimulation and drug administration, n=3-6. When multiple groups were analyzed, a oneway ANOVA followed by a Tukey’s posthoc test was used (Prism). The optogeneticsmicrodialysis experiments were analyzed using a two-way repeated-measures ANOVA
followed by a Tukey’s posthoc test (Prism). For all statistical analyses, significance was
determined using p<0.05.
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Chapter 3 THE EFFECT OF A2AR-D2R HETEROMERIZATION ON GI SIGNALING
THROUGH THE D2R

3.1 Introduction
The Gi-coupled D2R and the Gs-coupled A2AR are co-localized in the
striatum on GABAergic MSNs (Fuxe, Ferre et al. 2007). Biochemical pull down assays
and biophysical BRET and FRET techniques have provided evidence that the A2AR and
D2R form a functional heteromeric complex (Canals, Marcellino et al. 2003). Previous
studies determined that the heteromer interface depends on electrostatic interactions
between an arginine rich region in the third intracellular loop of the D2R and a
phosphorylated serine (Ser374) in the carboxy terminus of the A2AR (Borroto-Escuela,
Marcellino et al. 2010). Homomeric D2R and A2AR receptor signaling cascades have
been well established, but the implications of receptor heteromerization are not well
understood. In MSNs, homomeric D2R signaling through the Gi/o protein inhibits
neuronal excitability. In contrast, the Gs/olf protein-coupled A2AR is critical in modulating
the excitation of striatal neurons by antagonizing the D2R through the formation of a
higher order oligomer (Fuxe, Ferre et al. 2007). Thus, through heteromer crosstalk A2AR
agonists act as D2R antagonists exerting an excitatory role on the function of MSNs
(Ferre, Quiroz et al. 2008). This receptor-mediated antagonism has important
implications for the indirect motor pathway circuitry in the basal ganglia. In cases of
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Parkinson’s disease, decreased dopaminergic signaling through the D2R along with
antagonism of the A2AR on residual D2R signaling through heteromerization increases
inhibitory GABAergic projections from the basal ganglia to the ventrolateral thalamus,
disrupting excitatory thalamic output to the motor cortex. Thus, A2AR antagonists are
being explored in clinical trials as antiparkinsonian therapeutics to alleviate A2ARmediated inhibition on D2R signaling (Quiroz et al. 2009) The A2AR-D2R heteromer is an
emerging target for Parkinson’s disease pharmacotherapy and understanding the
signaling balance through the heteromer is paramount.
In this study, we examine the effect of A2AR-D2R heteromerization on the
pharmacology of D2R signaling. Previous studies lead us to postulate that the A2AR and
D2R receptor are inversely coupled through heteromeric assembly similar to the
serotonin 2A- metabotropic glutamate type 2 receptor heteromer, which was previously
characterized by our lab (Fribourg, Moreno et al. 2011). Therefore, we hypothesize
A2AR-D2R heteromerization induces reciprocal antagonism whereby A2AR receptor
stimulation inhibits D2R signaling making the combination of D2R agonists and A2AR
antagonists or inverse agonists promising new therapeutics for Parkinson’s disease
because they maximize dopaminergic signaling. In order to test this hypothesis, we
have developed electrophysiological assays to study A2AR-D2R heteromer cross
signaling by expressing the GPCRs together with reporter channels in the Xenopus
oocyte heterologous expression system. Our electrophysiological assay is innovative in
that it allows us to control the conditions of heteromerization and tease apart the
differences from protomer signaling. By monitoring the current through the reporter
channel, we anticipate perfusion of specific ligand combinations targeting the A2AR-D2R
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heteromer will maximize GPCR signaling versus individual drug administration targeting
A2ARs or D2Rs.
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3.2 Results
G protein-sensitive inwardly rectifying K+ (GIRK) channels can serve as
reporters for Gi signaling through the D2R and Gs signaling through the A2AR (HatcherSolis, Fribourg et al. 2014). We chose the GIRK1/2 (G1/2) channel heterotetramer as a
reporter for G protein signaling because it is co-localized with the A2AR and D2R on the
postsynaptic site of dopaminergic MSNs. The G1/2 channel can be used as a reporter
for Gi or Gs signaling because GPCR activation results in liberation of the beta gamma
subunits (Gβγ) from the G protein heterotrimer that bind to a cleft formed by cytosolic
loops of adjacent subunits of the channel, potentiating its current (Mahajan, Ha et al.
2013). For our electrophysiological assays, we used Xenopus laevis oocytes as our
heterologous expression system and conducted two-electrode voltage-clamp recordings
using a voltage ramp protocol form -80 mV to +80 mV two days following cRNA
injection.
Figure 3.1 establishes G1/2 as a suitable reporter for D2R signaling. Basal G1/2
current in a high potassium (HK) buffer is not sensitive to 1 µM dopamine (DA) without
D2R co-expression (Fig. 3.1A). However, when G1/2 is co-expressed with the D2R,
there is a robust inward DA-elicited current (Fig.3.1B). The DA-elicited current is Gimediated as it is blocked by co-expression of pertussis toxin (PTX, Fig. 3.1C). PTX
abrogates Gi signaling by catalyzing the ADP-ribosylation of the Gαi subunit, physically
uncoupling the G protein from the GPCR (Hatcher-Solis, Fribourg et al. 2014). The DA-
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elicited current is also Gβγ-mediated as the current is attenuated by co-expression of
the pleckstrin homology domain of the beta adrenergic receptor kinase (βARK), a well
characterized Gβγ scavenger (Fig. 3.1D). Since βARK has been implicated to bind PIP2
and also GIRK channels directly, we used an additional Gβγ scavenger, myristoylated
phosducin (Fig. 3.1E) (Hatcher-Solis, Fribourg et al. 2014). Figure 3.1F is a summary
figure establishing the DA-elicited current (-17.23 ± 2.35 µA) as significantly different
from the G1/2 basal current (-7.32 ± 0.43 µA). Paired t-tests were performed to compare
“Basal” to “Basal + Agonist” currents in the five different expression groups. Significant
effects were noted in the “G1/G2 + D2R” expression group, p=0.005. Only the Barium
(Ba2+)-sensitive current was analyzed for figure 3.1F as Ba2+ is a blocker of GIRK
currents. After characterizing homomeric D2R signaling, we pursued an
electrophysiological assay to assess the effect of A2AR-D2R heteromerization on
homomeric D2R signaling.
After characterizing Gi signaling through the D2R, we tested the effect of
heteromerization. A2ARs and D2Rs are known to have two types of interactions: 1) direct
receptor-receptor interactions or heteromerization and 2) downstream signaling from
separate populations of homomers converging on effector molecules (Ferre, Agnati et
al. 2007). When assessing the effect of A2AR-D2R heteromerization, we blocked the
downstream signaling of the adjacent GPCR so changes in homomeric signaling should
result from heteromerization. Thus, while examining D2R-mediated signaling through
the A2AR-D2R heteromer, we did not co-express Gαs to affect A2AR signaling (Lim,
Dascal et al. 1995).
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To test the effect of heteromerization on Gi signaling through the D2R, different
D2R:A2AR cRNA ratios were used to achieve the level of protein expression for maximal
signaling through heteromerization. Downstream A2AR signaling was blocked by not
overexpressing Gαs since the endogenous level of Xenopus Gαs is not sufficient to elicit
signaling through the A2AR (Lim, Dascal et al. 1995). Compared to Gi signaling through
the D2R (Fig. 3.2A), there is decreased D2R signaling with A2AR co-expression
(D2R:A2AR) in the following ratios: 1:1 (Fig. 3.2B), 1:2 (Fig. 3.2C), and 2:1 (Fig. 3.2D).
Figure 3.2E is a summary figure of the normalized Ba2+-sensitive, DA-induced current
showing A2AR co-expression significantly reduces Gi signaling through the D2R in all
ratios tested. Paired t-tests with a Bonferroni correction were performed to compare
normalized Gi activity with and without A2AR co-expression (1:0, 2.84 ± 0.14). Significant
effects were noted in all the D2R:A2AR expression groups: 1:1 (2.26 ± 0.12), 1:2 (2.06 ±
0.09), and 2:1 (1.95 ± 0.10), p<0.05. In summary, we have established an
electrophysiological assay demonstrating that the unliganded A2AR is a negative
allosteric modulator for D2R signaling.
Next, we evaluated whether A2AR ligands could crosstalk to Gi signaling through
the D2R. The ratio of D2R:A2AR used was 2:3 (0.5 ng to 0.75 ng) because previous
studies established that this ratio is most similar to that seen in the striatum. D2R
signaling (Figs. 3.3A and 3.4A) and the effect of A2AR co-expression (Figs. 3.3B and
3.4B) were repeated to compare Gi activity within the same experiment. The A2AR
agonist CGS 21680 partially removed the inhibition of the unliganded A2AR on the D2R,
but did not restore D2R signaling to the level observed when the D2R is expressed alone
(Figs. 3.3C and 3.4C). Perfusion of the A2AR antagonists KW-6002 (Fig. 3.3D) and ZM
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241385 (Fig. 3.4D) resulted in Gi signaling that was not significantly different from that
displayed with the D2R. Interestingly, the combination of CGS 21680 and the A2AR
antagonists KW-6002 (3.3E) and ZM 241385 (Fig. 3.4E) resulted in Gi signaling through
the D2R that was not significantly different from Gi signaling though the D2R protomer.
Figures 3.3 and 3.4 demonstrate that the addition of A2AR ligands can further modulate
the inhibition of the unliganded A2AR on D2R signaling.
After evaluating A2AR-D2R crosstalk, we sought to determine if the allosteric
modulation of the A2AR on the D2R was due to heteromerization; therefore, we mutated
the heteromer interface (Fig. 3.5) and tested the A2AR ligands on homomeric D2R
signaling (Fig. 3.7). We utilized A2AR(S374A) to disrupt heteromerization and test if this
mutant affected the ability of A2AR ligands to crosstalk to the D2R. In all ligand
combinations tested, co-expressing A2AR(S374A) with the WT D2R abrogated the effect
of the A2AR ligands CGS 21680 (Fig. 3.5C), ZM 241385, (Fig. 3.5D) KW-6002 (Fig.
3.5E), CGS 21680 + ZM 241385 (Fig.3.5F), and CGS 21680 + KW-6002 (Fig. 3.5G) on
D2R signaling. In figure 3.6, the A2AR mutant A2AR(S374A) (3.6B) was shown to have Gi
signaling that was not significantly different from the WT A2AR (Fig. 3.6A). Thus, the
difference in function between A2AR(S374) and A2AR was not the reason for the
termination of the A2AR-mediated effects on D2R signaling. We also tested all of the
A2AR ligands used in previous figures to assess if these ligands exerted independent
effects on D2R signaling. Compared to dopamine-elicited D2R signaling, neither CGS
21680, ZM 241385, nor KW-6002 had any effect on D2R signaling. Furthermore, these
ligands did not have any effect on basal D2R signaling. Figures 3.5, 3.6, and 3.7 provide

47

additional evidence that the antagonism of A2AR ligands on D2R signaling was due to
heteromerization.
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3.3 Discussion
GPCR heteromers are emerging therapeutic targets for a plethora of diseases
due to cell-specific localization and distinct pharmacology from their homomeric or
monomeric counterparts (Ferre, Quiroz et al. 2008). The A2AR-D2R heteromer is of
interest since the reciprocal antagonistic interaction can be exploited to develop novel
antiparkinsonian therapeutics (Ferre, Agnati et al. 2007). Signaling through the D2R
inhibits the neuronal excitability of striatal enkephalinergic MSNs allowing normal
circuitry through the indirect motor pathway to the motor cortex resulting in the initiation
of movement. Through heteromerization, the A2AR antagonizes D2R signaling
modulating neuronal excitability and GABA release. In cases of Parkinson’s disease,
decreased homomeric D2R signaling combined with heteromer-mediated A2AR
antagonism on residual dopaminergic signaling increases inhibitory GABAergic
projections from the basal ganglia to the ventrolateral thalamus disrupting thalamic
output to the motor cortex to initiate movement (Kull, Ferre et al. 1999). Consequently,
the A2AR antagonists istradefylline (KW-6002), vipadenant, and tozadenant have been
explored for Parkinson’s disease pharmacotherapy in clinical trials (Jenner 2003).
Therefore, characterization of A2AR-D2R heteromer signaling could elucidate the
molecular mechanism for A2AR antagonists potentiating D2R signaling and being
efficacious therapeutics for Parkinson’s disease.
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In the current study, we have developed electrophysiological assays to
characterize the effect of A2AR-D2R heteromerization on signaling through the D2R.
Two-electrode voltage-clamp was used to measure current through the GIRK1/2
channel, which served as a reporter for G protein signaling through the D2R, or A2ARD2R heteromer in the Xenopus laevis oocyte heterologous expression system. Our
results demonstrate GIRK channels can serve as reporters for Gi-coupled signaling
through the D2R (Fig. 3.1). Previous studies revealed A2AR antagonism of D2R signaling
effects on neurotransmitter release, neural firing, and behavior (Agnati, Ferre et al.
2003, Ferre, Agnati et al. 2007, Azdad, Gall et al. 2009). Consistent with previous
findings, our work demonstrates that mere co-injection of the A2AR reduces D2R
signaling (Fig. 3.2). Our study is the first to demonstrate that the unliganded A2AR
antagonizes Gi signaling through the D2R. Furthermore, the addition of the A2AR ligand
agonist CGS 21680 in combination with dopamine relieved the inhibition of the
unliganded A2AR on D2R signaling even though Gi signaling was not equivalent to the
level when the D2R is expressed alone. In contrast, the combination of A2AR antagonists
KW-6002 and ZM 241385 with dopamine inhibited D2R signaling similarly to the
unliganded A2AR. The combination of CGS 21680 with either KW-6002 or ZM 241385
resulted in Gi signaling through the D2R that is similar to that displayed when the D2R is
expressed alone (Figs. 3.3, 3.4, and 3.8). Crosstalk was mediated by heteromerization
because abrogating the heteromer interface using A2AR(S374A) abolished the inhibition
of A2AR ligands on D2R signaling (Figs. 3.5, 3.6, and 3.8). Our data provide evidence at
the molecular level for the combination of agonists and antagonists for the A2AR
potentially being effective as putative antiparkinsonian therapeutics. These results are
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consistent with the findings of Bonaventura et al. 2015, which examined the effect of
A2AR ligands on D2R signaling at the second messenger and behavioral level. Overall,
we demonstrate that the A2AR antagonizes Gi-mediated D2R signaling through
heteromerization at the G protein level and we have developed an assay for the
screening of A2AR ligands against Gi signaling through the D2R.
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Figure 3.1. The GIRK1/2 (G1/2) channel is a suitable reporter or Gi signaling
through the D2R. Representative barium-sensitive traces of G1/2 currents obtained in
response to a high K+ solution (HK, solid line) and 1 µM dopamine (DA, dashed line) in
oocytes expressing G1 + G2 (3.1A), G1 + G2 + D2R (3.1B), G1 + G2 + D2R + PTX
(3.1C), G1 + G2 + D2R + βARK (3.1D), and G1 + G2 + D2R + PHOS (3.1E). Barium (3
mM Ba2+, dotted line) inhibited G1/2 and allowed for subtraction of G1/2 independent
currents. βARK and PHOS are proteins that bind Gβγ, acting as scavengers. Summary
figure where each bar represents the mean of n=5-6 experiments with error bars
depicting the standard error of the mean (3.1F). Significance was determined using a
paired t-test p<0.01.
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Figure 3.2. A2AR coexpression in various ratios to the D2R inhibits Gi signaling
through the D2R. Representative barium-sensitive traces of G1/2 currents obtained in
response to a high K+ solution (HK, solid line) and 1 µM dopamine (DA, dashed line) in
oocytes expressing G1 + G2 + D2R (1 ng, 3.2A), G1 + G2 + D2R + A2AR (0.5 ng, 3.2B),
G1 + G2 + D2R + A2AR (1 ng, 3.2C), and G1 + G2 + D2R + A2AR (2 ng, 3.2D). Barium (3
mM Ba2+, dotted line) inhibited G1/2 and allowed for subtraction of G1/2 independent
currents. Summary figure where each bar represents the mean of n=5-6 experiments
with error bars depicting the standard error of the mean (3.2E). Significance was
determined using a one-way ANOVA with a Tukey’s posttest, p<0.05.
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Figure 3.3. A2AR ligands crosstalk to the D2R. Representative barium-sensitive traces
of G1/2 currents obtained in response to a high K+ solution (HK, solid line) and 1 µM
dopamine (DA, dashed line); 1 µM dopamine + 10 µM CGS 21680 (DA + CGS, dashed
line); 1 µM dopamine + 10 µM KW-6002 (DA + KW, dashed line); or 1 µM dopamine +
10 µM CGS 21680 + 10 µM KW-6002 (DA + CGS + KW, dashed line). Oocytes
expressed G1 + G2 + D2R (0.5 ng, 3.3A), or G1 + G2 + D2R + A2AR (0.75 ng, 3.3B,
3.3C, 3.3D, 3.3E). Barium (3 mM Ba2+, dotted line) inhibited G1/2 and allowed for
subtraction of G1/2 independent currents. Summary figure where each bar represents
the mean of n=5-8 experiments with error bars depicting the standard error of the mean
(3.3F). Significance was determined using a one-way ANOVA with a Tukey’s posttest,
p<0.05.
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Figure 3.4. A2AR ligands crosstalk to the D2R continued. Representative bariumsensitive traces of G1/2 currents obtained in response to a high K+ solution (HK, solid
line) and 1 µM dopamine (DA, dashed line); 1 µM dopamine + 10 µM CGS 21680 (DA +
CGS, dashed line); 1 µM dopamine + 10 µM ZM 241385 (DA + ZM, dashed line); or 1
µM dopamine + 10 µM CGS 21680 + 10 µM ZM 241385 (DA + CGS + ZM, dashed line).
Oocytes expressed G1 + G2 + D2R (0.5 ng, 3.4A), or G1 + G2 + D2R + A2AR (0.75 ng,
3.4B, 3.4C, 3.4D, 3.4E). Barium (3 mM Ba2+, dotted line) inhibited G1/2 and allowed for
subtraction of G1/2 independent currents. Summary figure where each bar represents
the mean of n=5-8 experiments with error bars depicting the standard error of the mean
(3.3F). Significance was determined using a one-way ANOVA with a Tukey’s posttest,
p<0.05.

55

Figure 3.5. A2AR(S374A) abolishes crosstalk of A2AR ligands to Gi signaling
through the D2R. Representative barium-sensitive traces of G1/2 currents obtained in
response to a high K+ solution (HK, solid line) and 1 µM dopamine (DA, dashed line); 1
µM dopamine + 10 µM CGS 21680 (DA + CGS, dashed line); 1 µM dopamine + 10 µM
ZM 241385 (DA + ZM, dashed line) 1 µM dopamine + 10 µM KW-6002 (DA + KW,
dashed line); 1 µM dopamine + 10 µM CGS 21680 + 10 µM ZM 241385 (DA + CGS +
ZM, dashed line); or 1 µM dopamine + 10 µM CGS 21680 + 10 µM KW-6002 (DA +
CGS + KW, dashed line). Oocytes expressed G1 + G2 + D2R (0.5 ng, 3.5A), or G1 +
G2 + D2R + A2AR(S374A,0.75 ng, 3.5B, 3.5C, 3.5D, 3.5E, 3.5F, 3.5G). Barium (3 mM
Ba2+, dotted line) inhibited G1/2 and allowed for subtraction of G1/2 independent
currents. Summary figure where each bar represents the mean of n=5-8 experiments
with error bars depicting the standard error of the mean (3.5H). Significance was
determined using a one-way ANOVA with a Tukey’s posttest, p<0.05.

56

Figure 3.6. A2AR(S374A) is functionally similar to WT A2AR. Representative bariumsensitive traces of G1/2 currents obtained in response to a high K+ solution (HK, solid
line) and 10 µM CGS 21680 (CGS, dashed line) in oocytes expressing G1 + G2 + Gαs +
A2AR (3.6A), or G1 + G2 + Gαs + A2AR(S374A, 3.6B). Barium (3 mM Ba2+, dotted line)
inhibited G1/2 and allowed for subtraction of G1/2 independent currents. Summary
figure where each bar represents the mean of n=5-8 experiments with error bars
depicting the standard error of the mean (3.6C). Significance was determined using a
paired t-test, p<0.05.
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Figure 3.7. A2AR ligands do not agonize or antagonize homomeric D2R Gi activity.
Summary figure of oocytes expressing G1 + G2 + D2R where each bar represents the
mean of n=5-8 experiments with error bars depicting the standard error of the mean.
Oocytes were perfused with 1 µM Dopamine (DA), 10 µM CGS 21680 (CGS), 10 µM
ZM 241385 (ZM), 10 µM KW-6002 (KW), 1 µM DA + 10 µM CGS, 1 µM DA + 10 µM
ZM, or 1 µM DA + 10 µM KW. Significance was determined using a one-way ANOVA
with a Tukey’s posttest.
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Figure 3.8 Summary D2R Signaling. Perfusion of DA to an oocyte injected with cRNA for

the D2R, GIRK1, and GIRK2 leads to channel activation resulting in robust agonist-induced
current (left panel, 3.1B). Co-expression of the unliganded A2AR with blocked downstream
signaling results in a decrease of the DA-elicited current through the D2R (second panel, 3.4B).
Application of the A2AR agonist CGS-21680 results in a relief of the inhibition of the unliganded
A2AR. Application of the A2AR antagonists KW-6002 or ZM241385 results in inhibition similar to
that seen with the unliganded A2AR. Co-application of A2AR agonists and antagonists results in a
relief of inhibition similar to that seen with perfusion of CGS-21680 alone (third panel).
Disrupting the heteromer interface using A2AR(S374A) abrogates all crosstalk.
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Chapter 4 THE EFFECT OF HETEROMERIZATION ON GS SIGNALING THROUGH
THE A2AR

4.1 Introduction
The Gαs/olf-coupled A2AR and the Gαi/o-coupled D2R are two distinct GPCRs that
heteromerize in the striatopallidal GABA pathway (Ferre, Quiroz et al. 2008). Previous
studies determined that heteromerization depends on electrostatic interactions between
an arginine rich region in the third intracellular loop of the D2R and a phosphorylated
serine (Ser374) in the c-terminus of the A2AR (Borroto-Escuela, Marcellino et al. 2010).
The physiological relevance of the A2AR-D2R heteromer is based on receptor
antagonism. A2ARs antagonize the inhibitory role of D2Rs on neurotransmitter release
and neuronal firing. There is exaggerated antagonism of the D2R by the A2AR in
Parkinson’s disease patients due to decreased dopaminergic tone in the striatum (Kull,
Ferre et al. 1999). Therefore, A2AR antagonists are being explored as possible
therapeutics for Parkinson’s disease because they alleviate the A2AR inhibition
of the D2R (Fuxe, Ferre et al. 2007). A plethora of studies have explored the
antagonism of the A2AR on the D2R, but few studies have examined the antagonism of
the D2R on A2AR signaling. Fernández-Dueñas et al. 2013 provided evidence for D2R
agonists (e.g. apomorphine, rotigotine, and pramipexole) antagonizing A2AR agonist
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binding, but this study did not examine the effect of D2R ligands on A2AR signaling
(Fernandez-Duenas, Gomez-Soler et al. 2013). Therefore, we aim to further understand
A2AR signaling through the A2AR-D2R complex. We will study A2AR-D2R heteromer cross
signaling through the GS-coupled A2AR by expressing the GPCRs as well as reporter
channels using the Xenopus oocyte heterologous expression system. Our
electrophysiological assay is innovative in that it will allow us to control the conditions of
heteromerization to tease apart the differences from protomer signaling. Based on
previous studies, we hypothesize that D2R agonists will inhibit Gs signaling through the
A2AR and specific ligand combinations targeting the A2AR-D2R heteromer will be more
effective in maximizing GPCR signaling than individual drug administration.
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4.2 Results
Lim et al. 1995 demonstrated in Xenopus oocytes that GIRK channels could
couple to the β2 adrenergic receptor when Gαs is over expressed with the channel.
Using a similar approach, we determined G1/2 as a suitable reporter for Gs signaling
through the A2AR when Gαs is over expressed (Lim, Dascal et al. 1995). Figures 4.1A-C
serve as negative controls establishing that the G1/2 channel can only couple to Gas
with current elicited by the A2AR agonist CGS-21680 (CGS) when the channel is coexpressed with both the A2AR and Gas. Figure 4.1D shows 10 µM CGS induces an
inward current mediated by Gs signaling through the A2AR when Gas, G1/2, and A2AR
are co-expressed validating G1/2 as a reporter for Gs signaling. Figure 4.1E
demonstrates the CGS-elicited current is Gβγ-mediated, as it is abolished by the Gβγ
scavenger βARK. Myristoylated phosducin was also used as a specific Gβγ scavenger
(Fig. 4.1F). Figure 4.1G is a summary figure of the Ba2+-sensitive current showing the
CGS-induced current (-11.58 ± 0.98 µA) is significantly different from G1/2 basal current
(-4.80 ± 0.30 µA). Paired t-tests were performed to compare “Basal” to “Basal +
Agonist” in the six different expression groups. Significant effects were noted in the “G1
+ G2 + Gαs + A2AR” expression group, p=0.02. Signaling through the A2AR was also
examined with PTX co-injection. Compared to CGS-elicited signaling through the A2AR
(Fig. 4.1D), addition of PTX reduced the basal G1/2 current and the CGS-induced
current (Figs. 4.2B,C). Paired t-tests were performed to compare “Basal” (-7.05 ± 0.66
µA) to “Basal (+ PTX)” current (-4.16 ± 0.61 µA) and “Agonist” (-3.78 ± 0.43 µA) to
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“Agonist (+ PTX)” (-2.82 ± 0.41 µA) current in the two different treatment groups,
p<0.05. A2AR-mediated Gαs signaling persisted in the presence of PTX confirming Gs
signaling is independent of Gi signaling in our assay. In summary, we have established
electrophysiological assays using G1/2 for signaling through the A2AR.
Adenosine (ADO), the nonselective endogenous ligand for the A2AR, was not
used in our assay for A2AR signaling because Xenopus oocytes have an endogenous
Gi-coupled adenosine type 1 receptor (A1R, Fig. 4.3D). In oocytes only injected with
G1/2 cRNA, ADO elicited a robust agonist-induced current (Fig. 4.3A). Furthermore, N6cyclopentyladenosine (CPA), a selective A1R agonist, stimulated agonist-induced
current (Fig. 4.3C) while CGS, a selective A2AR agonist, did not (Fig. 4.3B). Figure 4.3D
is a summary figure of the Ba2+-sensitive current showing the ADO-induced current (7.79 ± 0.58 µA) and the CPA-induced current (-11.36 ± µA) are significantly different
from the G1/2 basal current for the “ADO” (-3.19 ± 0.14 µA) and “CPA” (-5.46 ± 0.50 µA)
treatment groups. Paired t-tests were performed to compare “Basal” to “Basal +
Agonist” in the three different treatment groups. Significant effects were noted in the
“ADO” and “CPA” expression groups, p<0.01.
After characterizing protomeric signaling through the A2AR, we tested the effect
of heteromerization. A2ARs and D2Rs are known to have two types of interactions: 1)
direct receptor-receptor interactions or heteromerization and 2) downstream signaling
from separate populations of homomers converging on effector molecules (Ferre et al.
2007) When assessing the effect of A2AR-D2R heteromerization, we blocked the
downstream signaling of the adjacent GPCR so changes in signaling should result from
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heteromerization. A2AR-mediated signaling through the A2AR-D2R heteromer was
evaluated with PTX co-expression to abrogate D2R signaling.
Our lab is the first to examine the functional implications of A2AR-D2R
heteromerization on A2AR signaling using electrophysiology (Fig. 4.4). We tested the
effect of heteromerization on Gs signaling through the A2AR using different A2AR:D2R
cRNA ratios to achieve the level of protein expression for maximal cross-signaling. PTX
was co-expressed to block downstream D2R signaling. Compared to Gs signaling
through the A2AR (Fig. 4.4A), there is decreased A2AR signaling with D2R co-expression
(A2AR:D2R) in the following ratios: 1:1 (Fig. 4.4B), 1:2 (Fig. 4.4C), and 2:1 (Fig. 4.4D).
Figure 4.4E is a summary figure of the normalized Ba2+ -sensitive, CGS-induced current
showing D2R co-expression significantly reduces Gs signaling through the A2AR in all
ratios tested. A one-way ANOVA with a Tukey’s posttest was performed to compare
normalized Gs activity with and without D2R co-expression (1:0, 2.12 ± 0.23). Significant
effects were noted in all the A2AR:D2R expression groups: 1:1 (1.64 ± 0.08), 1:2 (1.45 ±
0.08), and 2:1 (1.39 ± 0.05), p<0.05. Thus, we have established an electrophysiological
assay demonstrating that the D2R antagonizes A2AR signaling.
Next, we evaluated whether D2R ligands could crosstalk to Gs signaling through
the A2AR. The ratio of D2R:A2AR used was 2:3 (0.5 ng to 0.75 ng) because previous
studies have established that this ratio is most similar to that seen in the striatum. A2AR
signaling (Fig. 4.5A) and the effect of D2R co-expression (Fig. 4.5B) were repeated to
compare Gs activity within the same experiment. Perfusion of the D2R agonist quinpirole
(Fig. 4.5C) or the D2R antagonists paliperidone (Fig. 4.5D) and amisulpride (Fig. 4.5E)
resulted in Gs signaling that was significantly decreased from that displayed with co-
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expression of the unliganded D2R. The combination of the D2R ligands quinpirole and
paliperidone inhibited Gs signaling through the A2AR at similar levels to that seen with
either ligand alone (4.5F). In contrast, the combination of the D2R ligands quinpirole and
amisulpride (4.5G) resulted in Gs signaling through the A2AR that was not significantly
different from protomeric levels. Figure 4.5 demonstrates that the addition of D2R
ligands can further modulate the inhibition of the unliganded D2R on A2AR signaling.
After evaluating A2AR-D2R crosstalk, we sought to determine if the allosteric
modulation of the D2R on the A2AR was due to heteromerization; therefore, we mutated
the heteromer interface (Fig. 4.6) and tested the D2R ligands on protomeric A2AR
signaling (Fig. 4.8). We mutated arginines 217, 219, 220, 222, 267, 268, and 269 along
with lysines 218 and 221 in the third intracellular loop of the D2R to alanine to disrupt
heteromerization and termed the mutant D2R(9A). We utilized D2R(9A) to disrupt
heteromerization and test if this mutant affected the ability of D2R ligands to crosstalk to
the A2AR. In all ligand combinations tested, co-expressing D2R(9A) with the WT A2AR
abrogated the effect of the D2R ligands quinpirole (Fig. 4.6C), paliperidone (Fig. 4.6D),
amisulpride (Fig. 4.6E), quinpirole + paliperidone (Fig. 4.6F), and quinpirole +
amisulpride (Fig. 4.6G) on A2AR signaling. In figure 4.7, the D2R mutant D2R(9A, Fig.
4.7B) was shown to have Gi signaling that was not significantly different from the WT
A2AR (Fig. 3.6A). Thus, the difference in function between D2R(9A) and D2R was not the
reason for the termination of the D2R-mediated effects on A2AR signaling. We also
tested all of the D2R ligands used in previous figures to assess if these ligands exerted
independent effects on A2AR signaling. Compared to CGS 21680-elicited A2AR
signaling, neither quinpirole, paliperidone, nor amisulpride had any effect on protomeric
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A2AR signaling. Furthermore, these ligands did not have any effect on basal A2AR
signaling. Figures 4.6, 4.7, and 4.8 provide additional evidence that the antagonism of
A2AR ligands on D2R signaling was due to heteromerization.
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4.3 Discussion
The A2AR-D2R heteromer is an emerging therapeutic target for Parkinson’s
disease because of the established antagonism of the A2AR on the D2R. In Parkinson’s
disease, there is a loss of dopaminergic innervation to the striatum and the A2ARs
antagonize residual D2R signaling. Therefore, most studies have focused on elucidating
the antagonism of the A2AR on the D2R targetting A2AR antagonists as antiparkinsonian
therapeutics (Jenner 2003). The A2AR antagonist KW-6002 is currently used in Japan to
treat Parkinson’s disease and several other A2AR antagonists are in clinical trials (Chen,
Wang et al. 2013). Compared to the extensive research characterizing A2AR
antagonism of the D2R, much less is known of the D2R-mediated antagonism of the
A2AR. Various studies have detailed the antagonism of the D2R on the A2AR at the
second messenger level through the canonical Gi signaling pathway inhibiting adenylate
cyclase, cAMP accumulation, PKA phosphorylation of downstream effectors, and gene
expression of c-fos and preproenkephalin (Ferre, Quiroz et al. 2008). However, this
negative allosterism at the second messenger level is not heteromer dependent. Fewer
studies have focused on the therapeutic potential of D2R agonists that crosstalk to the
A2AR through heteromerization inhibiting A2AR ligand binding and signaling. In 2013,
Fernández-Dueñas and colleagues used real-time FRET and flow cytometry in
transfected cells to provide evidence for antiparkinsonian D2R agonists antagonizing
A2AR agonist binding. More studies are needed to examine the effect of D2R ligands on
A2AR signaling through heteromerization as this could lead to novel antiparkinsonian
therapeutics targeting the D2R.
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Expanding on the Fernández-Dueñas study, we developed an
electrophysiological assay to examine the effect of A2AR-D2R heteromerization on A2AR
signaling at the G protein level. We used Xenopus laevis occytes as our heterologous
expression system and the GIRK1/2 channel as a reporter for A2AR signaling by over
expressing Gαs (Fig. 4.1). In our assay, co-expression of the unliganded D2R inhibits
A2AR signaling (Fig. 4.4). Our study is one of the first to demonstrate that the unliganded
D2R antagonizes Gs signaling through the A2AR. Furthermore, the addition of the D2R
agonist quinpirole or the D2R antagonists paliperidone and amisulpride further inhibited
signaling through the A2AR (Fig. 4.5 and Fig. 4.9). Our work provides evidence for both
D2R agonists and antagonists diminishing Gs signaling through the A2AR. The
combination of the D2R ligands quinpriole and paliperidone inhibited A2AR signaling
similarly to each ligand when administered alone. In contrast, co-administration of
quinpirole and amisulpride resulted in Gs signaling through the A2AR that is similar to
protomeric levels (Fig. 4.5). Crosstalk was mediated by heteromerization because
abrogating the heteromer interface using D2R(9A) abolished the inhibition of D2R
ligands on A2AR signaling (Figs. 4.6, 4.7, and 4.9). Overall, we have demonstrated that
the D2R antagonizes Gs-mediated A2AR signaling through heteromerization at the G
protein level and we have developed an assay for the screening of D2R ligands against
Gs signaling through the A2AR.
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Figure 4.1 The GIRK1/2 (G1/2) channel is a suitable reporter for Gs signaling
through the A2AR. Representative barium-sensitive traces of G1/2 currents obtained in
response to a high K+ solution (HK, solid line) and 10 µM CGS-21680 (CGS, dashed
line) in oocytes expressing G1 + G2 (4.1A), G1 + G2 + Gαs (4.1B), G1 + G2 + A2AR
(4.1C), G1 + G2 + Gαs + A2AR (4.1D), G1 + G2 + Gαs + A2AR + βARK (4.1E), and G1 +
G2 + Gαs + A2AR + PHOS (4.1F). Barium (3 mM Ba2+, dotted line) inhibited G1/2 and
allowed for subtraction of G1/2 independent currents. Summary figure where each bar
represents the mean of n=5-6 experiments with error bars depicting the standard error
of the mean (4.1G). Significance was determined using a paired t-test p<0.03.
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Figure 4.2 Gs signaling through the A2AR in the presence of PTX. Representative
barium-sensitive traces of G1/2 currents obtained in response to a high K+ solution (HK,
solid line) and 10 µM CGS-21680 (CGS, dashed line) in oocytes expressing G1 + G2 +
Gαs + A2AR (4.2A) and G1 + G2 + Gαs + A2AR + PTX (4.2B). Barium (3 mM Ba2+,
dotted line) inhibited G1/2 and allowed for subtraction of G1/2 independent currents.
Summary figure where each bar represents the mean of n=5-6 experiments with error
bars depicting the standard error of the mean (4.2C). Significance was determined with
a paired t-test, p<0.05.
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Figure 4.3 Xenopus oocytes have an endogenous Gi-coupled A1R. Representative
barium-sensitive traces of G1/2 currents obtained in response to a high K+ solution (HK,
solid line) and 10 µM adenosine (ADO, dashed line) the nonselective endogenous
ligand for adenosine receptors (4.3A), 10µM CGS-21680 (CGS, dashed line) the
selective agonist for the A2AR (4.3B), and 10 µM N6-cyclopentyladenosine (CPA,
dashed line) the selective agonist for the A1R (4.3C). Barium (3 mM Ba2+, dotted line)
inhibited G1/2 and allowed for subtraction of G1/2 independent currents. Summary
figure where each bar represents the mean of n=5-6 experiments with error bars
depicting the standard error of the mean (4.3D). Significance was determined using a
paired t-test p<0.01.
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Figure 4.4 The effect of D2R co-expression on Gs signaling through the A2AR.
Representative barium-sensitive traces of G1/2 currents obtained in response to a high
K+ solution (HK, solid line) and 10 µM CGS-21680 (CGS, dashed line) in oocytes
expressing G1, G2, the A2AR, PTX and D2R in the following ratios: 1:0 (4.4A), 1:1
(4.4B), 1:2 (4.4C), and 2:1 (4.4D). Barium (3 mM Ba2+, dotted line) inhibited G1/2 and
allowed for subtraction of G1/2 independent currents. Summary figure of normalized Gs
activity (Agonist + Basal Current/ Basal Current) where each bar represents the mean of
n=4-6 experiments with error bars depicting the standard error of the mean (4.4E).
Significance was determined using a one-way ANOVA with a Tukey’s posthoc test,
p<0.05.
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Figure 4.5 D2R ligands crosstalk to the A2AR. Representative barium-sensitive traces
of G1/2 currents obtained in response to a high K+ solution (HK, solid line) and 10 µM
CGS 21680 (CGS, dashed line); 10 µM CGS 21680 + 1 µM quinpirole (CGS + QUIN,
dashed line); 10 µM CGS 21680 + 10 µM paliperidone (CGS + PAL, dashed line); or 10
µM CGS 21680 + 10 µM amisulpride (CGS + ASUL, dashed line); 10 µM CGS 21680 +
1 µM quinpirole + 10 µM paliperidone (CGS + QUIN + PAL, dashed line); or 10 µM CGS
21680 + 1 µM quinpirole + 10 µM amisulpride. Oocytes expressed G1 + G2 + Gαs +
PTX+ A2AR (0.75 ng, 4.5A), or G1 + G2 + D2R + PTX+ Gαs + A2AR (0.75 ng, 4.5B,
4.5C, 4.5D, 4.5E, 4.5F, 4.5G). Barium (3 mM Ba2+, dotted line) inhibited G1/2 and
allowed for subtraction of G1/2 independent currents. Summary figure where each bar
represents the mean of n=5-8 experiments with error bars depicting the standard error
of the mean (4.5H). Significance was determined using a one-way ANOVA with a
Tukey’s posthoc test, p<0.05.
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Figure 4.6 D2R-9A disrupts the allosteric modulation of the D2R on the A2AR. We
mutated arginines 217, 219, 220, 222, 267, 268, and 269 along with lysines 218 and
221 in the third intracellular loop of the D2R to alanine to disrupt heteromerization and
termed the mutant D2R D2R(9A). Representative barium-sensitive traces of G1/2
currents obtained in response to a high K+ solution (HK, solid line) and 10 µM CGS
21680 (CGS, dashed line); 10 µM CGS 21680 + 1 µM quinpirole (CGS + QUIN, dashed
line); 10 µM CGS 21680 + 10 µM paliperidone (CGS + PAL, dashed line) 10 µM CGS
21680 + 10 µM amisulpride (CGS + ASUL, dashed line); 10 µM CGS 21680 + 1 µM
quinpirole + 10 µM paliperidone (CGS + QUIN + PAL, dashed line); or 10 µM CGS
21680 + 1 µM quinpirole + 10 µM amisulpride (CGS + QUIN + ASUL, dashed line).
Oocytes expressed G1 + G2 + Gαs + PTX + A2AR (0.75 ng, 4.6A), or G1 + G2 +
D2R(9A)+ PTX + Gαs + A2AR(0.75 ng, 4.6B, 4.6C, 4.6D, 4.6E, 4.6F, 4.6G). Barium (3
mM Ba2+, dotted line) inhibited G1/2 and allowed for subtraction of G1/2 independent
currents. Summary figure where each bar represents the mean of n=5-8 experiments
with error bars depicting the standard error of the mean (4.6H). Significance was
determined using a one-way ANOVA with a Tukey’s posttest, p<0.05.
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Figure 4.7 D2R-9A is functionally similar to WT D2R. Representative barium-sensitive
traces of G1/2 currents obtained in response to a high K+ solution (HK, solid line) and 1
µM dopamine (DA, dashed line) in oocytes expressing G1 + G2 + D2R (A), or G1 + G2
+ D2R(9A) (B). Barium (3 mM Ba2+, dotted line) inhibited G1/2 and allowed for
subtraction of G1/2 independent currents. Summary figure where each bar represents
the mean of n=5-8 experiments with error bars depicting the standard error of the mean
(C). Significance was determined using a paired t-test, p<0.05.
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Figure 4.8 D2R ligands do not agonize or antagonize homomeric A2AR Gs activity.
Summary figure of oocytes expressing G1 + G2 + Gαs + A2AR where each bar
represents the mean of n=5-8 experiments with error bars depicting the standard error
of the mean. Oocytes were perfused with 10 µM CGS 21680 (CGS), 1 µM Quinpirole
(QUIN), 10 µM Paliperidone (PAL), 10 µM Amisulpride (ASUL), 10 µM CGS + 1 µM
QUIN, 10 µM CGS + 10 µM PAL, or 10 µM CGS + 10 µM ASUL. Significance was
determined using a one-way ANOVA with a Tukey’s posthoc test.
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Figure 4.9 Summary A2AR Signaling. Perfusion of CGS to an oocyte injected with cRNA

for the A2AR, PTX, Gαs, GIRK1, and GIRK2 leads to channel activation resulting in robust
agonist-induced current (left panel). Co-expression of the unliganded D2R with blocked
downstream signaling results in a decrease of the CGS-elicited current through the A2AR
(second panel). Application of the D2R agonist Quinpirole results in increased inhibition
compared to the unliganded D2R. Application of the D2R antagonists KW-Paliperidone or
Amisulpride also results in increased inhibition compared to that seen with the unliganded D2R.
Co-application of the D2R agonist Quinpirole and antagonist amisulpride results in a relief of
inhibition (third panel). Disrupting the heteromer interface using D2R(9A) abrogates all crosstalk.

77

Chapter 5 OPTOGENETIC-MICRODIALYSIS ASSAY TO ASSESS THE
PRESYNAPTIC PROFILE OF A2AR ANTAGONISTS

5.1 Introduction
Smooth motor function is achieved through counterbalancing the activating and
inhibiting influences of the direct and indirect pathways of the striatum. Dopaminergic
innervation of the striatum results in motor activation by stimulating the direct pathway
via D1Rs and inhibiting the indirect pathway via D2Rs. Adenosine is also an important
neuromodulator in the striatum as stimulation or inhibition of postsynaptic A2ARs results
in the blockade or potentiation of D2R signaling (Quiroz, Lujan et al. 2009). Striatal
presynaptic A2ARs in glutamatergic terminals also affect motor activity by influencing
glutamate release in the direct pathway. A2AR antagonists that inhibit postsynaptic
A2ARs would be beneficial for the treatment of PD by inhibiting the indirect motor
pathway and increasing motor activity. However, A2AR antagonists that inhibit
presynaptic A2ARs would decrease glutamate release in the direct motor pathway
inhibiting motor activity. Thus, antiparkinsonian therapeutics targeting the A2AR should
have a higher affinity for postsynaptic versus presynaptic A2ARs. In 2011, Orrú and
colleagues used in vitro radioligand-binding and in vivo locomotor activity experiments
to determine the preferential presynaptic or postsynaptic action of A2AR antagonists.
Among the A2AR antagonists tested, SCH 442416 acted predominantly on presynaptic
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A2ARs; whereas, istradefylline (KW-6002) acted primarily on postsynaptic A2ARs. In this
study, we have utilized the optogenetic-microdialysis technique of Quiroz-Molina et al.
2016 to determine the presynaptic or postsynaptic preference of A2AR antagonists. We
used optogenetics to directly stimulate the striatal MSNs of the direct pathway to induce
glutamate release and microdialysis to determine if A2AR antagonists affect extracellular
glutamate concentrations. We anticipate A2AR antagonists that are potent inhibitors of
glutamate release act primarily presynaptically.
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5.2 Results
We used an optogenetic-microdialysis probe (Fig. 5.1) implanted in the striatum
of mice expressing AAV ChR2-EYFP to measure extracellular glutamate release in
response to light-induced activation of the cation ChR2 (Fig. 5.2). Optogenetic
stimulation resulted in rapid increases in the extracellular glutamate concentration
above basal levels (~300%). Termination of the optogenetic stimulation resulted in slow
decay of the extracellular glutamate concentration to basal levels. Administration of the
A2AR antagonist SCH 442416 via i.p. injection before optogenetic stimulation prevented
increases in the extracellular glutamate concentration (Fig. 5.4). SCH 442416 inhibited
glutamate release indicating that this drug acts preferentially on presynaptic A2ARs.
However, i.p. injection of the A2AR antagonist KW-6002 preceding optogenetic
stimulation had no significant effect on extracellular glutamate concentration
demonstrating that KW-6002 acts preferentially on postsynaptic A2ARs (Fig. 5.4). Figure
5.5 is a control experiment showing that the basal levels of glutamate in the mice across
all treatment groups (vehicle, SCH 442416 0.1 mg/kg, and KW-6002 1 mg/kg) obtained
prior to optogenetic stimulation are not significantly different as determined by a oneway ANOVA followed by a Tukey’s posthoc test (Prism). Thus, differences in basal
glutamate concentrations cannot account for the differences observed after optogenetic
stimulation. Erk 1/2 phosphorylation was also examined as an indicator of neuronal
activation. Robust ERK 1/2 labeling was present in the striatum of mice subjected to
laser stimulation while sparse labeling was observed in the motor cortex, the site of
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virus injection (Fig. 5.3). These experiments provide further evidence that optogenetic
stimulation in the striatum, the site of probe implantation, resulted in neuronal activation
and glutamate release.
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5.3 Discussion
The A2AR-D2R heteromer is an emerginig therapeutic target for Parkinson’s
disease based on receptor antagonism. A2AR antagonists that act postsynaptically
through the indirect motor pathway produce motor activation by potentiating D2R
signaling through A2AR-D2R interactions. However, A2AR antagonists that act
presynaptically through the direct motor pathway decrease motor activity by inhibiting
glutamate release. Therefore, it is essential to identify the presynaptic or postsynaptic
preference of A2AR antagonists to determine their therapeutic potential as
antiparkinsonian drugs. In this study, we have utilized an in vivo optogeneticmicrodialysis assay with the advantage of direct stimulation of glutamatergic terminals.
Optogenetic stimulation resulted in increases the extracellular concentration of
glutamate that were abrogated by pre-administration SCH 442416 (Fig. 5.4) Our results
are consistent with the findings of Orrú and colleagues, who determined the potent
activity of SCH 442416 on presynaptic A2ARs using in vitro radioligand binding and in
vivo locomotor experiments. Future studies will involve assaying more A2AR antagonists
especially the postsynaptic acting KW-6002 to see if this compound is able to inhibit
glutamate release in our assay. Our assay is useful for screening the presynaptic
activity of A2AR antagonists that are potential antiparkinsonian therapeutics.
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Figure 5.1 Optogenetic-microdialysis probe. Image of the hand made microdialysisoptogenetics probes with the semi-permeable microdialysis membrane, the
microdialysis inlet and outlet, and the fiber optic (left). Illuminated microdialysis tube with
laser stimulation (right).
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Figure 5.2 Schematic displaying timeline of unilateral AAV microinjection and
optogenetic-microdialysis experiment. WT C57BL/6 mice received unilateral
injections of adeno-associated virus (AAV) encoding channel rhodopsin 2 (ChR2) fused
to enhanced yellow fluorescent protein (EYFP) under control of the CaMKII neuronal
promoter. The coordinates of virus injection were 1.9 mm anterior, 1.6 mm lateral, and
1.8 mm ventral with respect to bregma to inject the virus into the motor cortex.
Approximately, 4 weeks after virus injection a modified microdialysis probe with an
embedded light-guiding optic fiber was implanted in the striatum. The coordinates for
probe implantation were 0.3 mm posterior, 2.7 mm lateral and 4.2 mm ventral with
respect to bregma in the striatum. Adapted from (Guo, Xiong et al. 2015).
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Figure 5.3 Confocal laser microscopy of coronal sections showing the
localization of ChR2-EYFP after unlilateral AAV microinjection in the motor cortex
and ERK phosphorylation immunohistochemistry. A Motor Cortex, scale bar 50 uM
B Inset C Localization of probe in striatum, scale bar 50 uM D Inset
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Figure 5.4 Effect of optogenetic stimulation in the striatum. Time course of
extracellular concentrations of glutamate in the striatum with i.p. injection of Vehicle, the
A2AR antagonist SCH 442416 0.1 mg/kg, or the A2AR antagonist KW-6002 1 mg/kg.
Negative time values represent basal glutamate before stimulation. Optogenetic
stimulation was for 20 minutes and is represented by the blue bar. Results are
expressed as mean ± SEM of percentages of glutamate normalized to basal values
before stimulation, n=3-6. Results were analyzed using a two-way repeated-measures
ANOVA with a Tukey’s posthoc test (Prism), * p≤0.05, ** p≤0.01, **** p≤0.0001.
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Figure 5.5 Basal Glutamate Concentration. Bar graph summarizing the basal levels
of glutamate obtained prior to optogenetic stimulation. Results are expressed as mean ±
SEM of glutamate concentration, n=3-6. There was no significant difference between
basal values in the three treatment groups (vehicle, SCH 442416 0.1 mg/kg, and KW6002 1 mg/kg) as determined by a one-way ANOVA followed by a Tukey’s posthoc test
(Prism).
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Chapter 6 CONCLUDING REMARKS

We investigated A2AR and D2R interactions using an electrophysiological, in vitro
assay with Xenopus oocytes as the heterologous expression system and an in vivo,
optogenetic-microdialysis assay in freely moving mice. Examining A2AR-D2R
heteromerization in a heterologous expression system allowed us to manipulate the
conditions of heteromerization by using interfering mutants. Our electrophysiological
assay also provided a membrane-delimited, direct readout of GPCR signaling at the G
protein level versus downstream second messengers. The Xenopus laevis heterologous
expression system also permitted titration of A2AR and D2R expression. Similarly, there
were many advantages to incorporating an in vivo assay into our studies. Using an in
vivo assay allowed us to use native neurons in the mouse striatum to explore A2AR and
D2R interactions. Through optogenetics, we were able to directly stimulate striatal
neurons and observe glutamate release. The optogenetic-microdialysis experiments
also provided physiological relevance to studies evaluating antiparkinsonian
therapeutics. Both our in vivo and in vitro assays provided a multitude of technical
advantages that allowed key insights into A2AR-D2R interactions.
In chapter 3, we utilized an electrophysiological assay with GIRK channels as
reporters for Gi signaling through the D2R to determine the effect of A2AR-D2R
heteromerization on Gi signaling through the D2R. The following conclusions can be
drawn from chapter 3 of this investigation. We determined that GIRK1/2 could serve as
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a reporter for Gi signaling through the D2R as the liberated βγ subunits from D2R
activation resulted in channel potentiation. Next, we co-expressed the A2AR along with
the D2R and found that the unliganded A2AR antagonizes dopamine-elicited Gi signaling
through the D2R in various ratios of overexpression of the two receptors. Our lab was
the first to uncover the effect of the unliganded A2AR on Gi signaling through the D2R.
We further perfused ligands to the A2AR to examine crosstalk. Perfusion of the A2AR
agonist CGS 21680 partially relieves the inhibition of the unliganded A2AR on D2R
signaling. Whereas, perfusing the A2AR antagonists ZM 241385 and KW-6002 both
inhibited dopamine-elicited signaling through the D2R. The combinations of A2AR
agonists (CGS 21680) and antagonists (KW-6002, ZM 241385) restored dopamineelicited Gi signaling through the D2R. We also utilized mutagenesis to examine whether
the aforementioned crosstalk was due to heteromerization. We discovered that the
ability of A2AR ligands to crosstalk to the D2R is mediated by A2AR-D2R heteromerization
as disrupting the heteromer interface using A2AR(S374A) relieves the inhibition of the
A2AR on the D2R. As a control, we tested all of the A2AR ligands used to ensure they
were specific for the A2AR and did not have any activity on the D2R.
Chapter 4 of this investigation focused on using an electrophysiological assay
with GIRK channels as reporters for Gs signaling through the A2AR to determine the
effect of A2AR-D2R heteromerization on Gs signaling through the A2AR. We
demonstrated that GIRK 1/2 can also serve as a reporter for Gs signaling through the
A2AR when Gαs is overexpressed and channel activation is mediated by the liberated βγ
subunits from A2AR activation. Additionally, the unliganded D2R antagonizes CGS
21680-elicited Gs signaling through the A2AR in various ratios of overexpression of the
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two receptors. Our results were the first to determine the effect of the unliganded D2R
on Gs signaling through the A2AR. Next, we examined crosstalk and found that
perfusion of the D2R agonist quinpirole further inhibits Gs signaling through the A2AR
compared to the unliganded D2R. Furthermore, both of the D2R antagonists amisulpride
and paliperidone inhibit Gs signaling through the A2AR similarly to quinpirole. The
combination of the quinpirole and amilsulpride, but not quinpirole and paliperidone
restored CGS 21680-elicited signaling through the A2AR to homomeric levels. We also
determined that the ability of D2R ligands to crosstalk to the A2AR was mediated by
heteromerization as disrupting the heteromer interface using D2R(9A, R217A, R219A,
R220A, R222A, R267A, R268A, R269A, K218A and K221A) relieves the inhibition of
the D2R on the A2AR. We also determined that quinpirole, amisulpride, and paliperidone
were specific for the D2R and did not any extraneous effect on the homomeric A2AR.
Our in vitro assays elucidated signaling through the A2AR-D2R heteromer and could
provide insight for future studies examining A2AR-D2R heteromerization.
In chapter 5, we utilized a recently developed optogenetic-microdialysis
technique to examine the presynaptic profile of A2AR antagonists on glutamatergic
afferents to the striatum. We used optogenetics to directly stimulate the striatal MSNs of
the direct pathway to induce glutamate release and microdialysis to determine if A2AR
antagonists affect extracellular glutamate concentrations. An optogenetic-microdialysis
probe was implanted in the striatum of mice expressing AAV ChR2-EYFP to measure
extracellular glutamate release in response to light-induced activation of the cation
ChR2. Optogenetic stimulation resulted in rapid increases in the extracellular glutamate
concentration above basal levels (~300%). Termination of the optogenetic stimulation
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resulted in slow decay of the extracellular glutamate concentration to basal levels.
Administration of the A2AR antagonist SCH 442416 before optogenetic stimulation
prevented increases in the extracellular glutamate concentration. However,
administration of the A2AR antagonist KW-6002 before optogenetic stimulation did not
have an effect on presynaptic glutamate release. SCH 442416 inhibited glutamate
release indicating that this drug preferentially acts on presynaptic A2ARs whereas the
inability of KW-6002 to affect presynaptic glutamate release indicates that this drug
preferentially acts on postsynaptic A2ARs. Erk 1/2 phosphorylation was also examined
as an indicator of neuronal activation. Robust ERK 1/2 labeling was present in the
striatum of mice subjected to laser stimulation while sparse labeling was observed in the
motor cortex, the site of virus injection. Our optogenetic-microdialysis assay is
useful for evaluating the therapeutic potential of antiparkinsonian drugs. Futures studies
for the in vitro experiments will include dose-response curves to evaluate how different
concentrations of A2AR and D2R ligands affect A2AR-D2R heteromer crosstalk. We are
also currently developing an optogenetic-locomotor activity assay to examine the
postsynaptic profile of A2AR antagonists.
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